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(57) ABSTRACT 
Disclosed herein is a simple method for the treatment of 
antigen-deficiency diseases, by orally administering to a Sub 
ject a therapeutically effective amount of the deficient anti 
gen, wherein the antigen is not present in a liposome. In one 
embodiment, the method increases hemostasis in a subject 
having hemophilia A or B, by orally administering to the 
hemophiliac atherapeutically effective amount of the appro 
priate clotting factor other than in a liposome, Sufficient to 
induce oral tolerance and Supply exogenous clotting factor to 
the subject. 
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1. 
INDUCTION OF TOLERANCEBY ORAL 
ADMINISTRATION OF FACTOR VIII AND 
TREATMENT OF HEMOPHILA 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This is a divisional of U.S. application Ser. No. 10/485,696, 
filed Feb. 2, 2004 now U.S. Pat. No. 7,220,718, which is a 
national stage under 35 U.S.C. S371 of International Appli 
cation No. PCT/US02/24544, filed Aug. 2, 2002, and claims 
the benefit of U.S. Provisional application No. 60/310,150, 
filed Aug. 3, 2001, which is hereby incorporated by reference 
in its entirety. 
FIELD 
This disclosure relates to methods for treating a subject 
Suffering from an antigen-deficiency which causes a disease, 
by orally administering a therapeutically effective amount of 
the deficient antigen to the Subject, Sufficient to induce oral 
tolerance and relieve symptoms of the disease. In one 
example, the disclosure relates to oral administration of clot 
ting factor VIII or IX for treating hemophilia A and B, respec 
tively. 
BACKGROUND 
Hemophilia A and B, caused respectively by decreased 
levels of clotting factor VIII (F.VIII) and IX (FIX) levels in 
peripheral blood, are the most common severe inherited 
bleeding disorders. Although purified clotting factors from 
human plasma can be infused into these patients to prevent or 
treat bleeding episodes, this poses the risk of spreading of 
diseases such as Creutzfeld-Jakob disease, HIV, and hepatitis 
C. Although recombinant clotting factor preparations are 
available, the supply is insufficient to cover the world-wide 
demand. 
As an alternative to generating recombinant clotting fac 
tors in cell culture, the use of transgenic animals as bioreac 
tors for the production of clinically useful quantities of pro 
teins has been proposed. The transgenic animal expresses the 
desired protein in a body fluid, such as milk, from which the 
protein can readily be isolated. Transgenic pigs that secrete 
F.VIII (U.S. Pat. No. 5,880,327 to Lubon et al.) or F.IX (Van 
Cott et al. 1999. Genet. Anal. 15:155-60) in their milk were 
generated using gene constructs that have regulatory 
sequences from the gene for mouse whey acidic protein (the 
4.2 kb 5’ promoter of WAP), in combination with the cDNA 
sequence encoding human F.VIII or F.IX. F.VIII pigs secrete 
2.7 ug/ml of human F.VIII into milk (Paleyanda et al. 1997. 
Nat. Biotech. 15:971), while F.IX pigs secrete 2.5 g/L of 
human F.IX into milk, and the factor is biologically active as 
measured by an activated partial thromboplastin time assay 
(APTT). 
Therefore, large amounts of functional protein can be 
obtained from FIX pigs, which is purified from the milk, and 
Subsequently administered intravenously (i.v.) to a hemo 
philiac patient. However, it has previously been thought that 
oral administration of F.VIII or F.IX results in degradation 
and/or inactivation of the protein due to the acidic and enzy 
matic composition of the stomach. For example, U.S. Pat. No. 
4,348,384 to Horikoshi et al. teaches the administration of an 
oral composition containing purified F.VIII or F.IX encapsu 
lated in a liposome along with a protease inhibitor, for the 
purpose of evading gastric inactivation of the therapeutic 
protein. 
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One complication that results from i.v. administration of 
F.VIII or F.IX is that up to 25% of hemophiliacs develop 
inhibitors, such as antibodies against F.VIII or F.IX that inac 
tivate their procoagulant activity (Fields et al. 2000. Mol. 
Ther: 3:225-35; Bristoletal. 2001. Hum. Gene Ther: 12:1651 
61; Geet al. 2001. Blood 97:3733-7: Brinkhous et al. 1996. 
Blood 88:2603-10). Most inhibitory antibodies develop in 
severely affected patients who have little or no circulating 
F.IX or F.VIII antigen due to genetic deletion. However, 
patients with a family history of inhibitor development, 
severe disease, older age or higher numbers of clotting factor 
replacement episodes, also have a higher incidence of devel 
oping these inhibitors (Roberts. 1997. Inhibitors and their 
management. In Hemophilia & Other inherited bleeding dis 
orders. Rizza & Lowe, eds. W B Saunders Company Ltd., 
London, p. 365.). The inhibitors can completely inhibit the 
activity of infused clotting factor and make further treatment 
difficult. 
One means of reducing clotting factor antibodies is the 
induction of immune tolerance to the clotting factors. For 
example, Roberts (JAMA 259:84-5, 1988) reviews studies in 
which F.VIII was injected at high concentrations. Although 
some studies reported that the level of anti-factor VIII anti 
bodies decreased, due to the high doses required, the method 
was never widely used because it was prohibitively expen 
sive. Oral administration of F.VIII as a means to prevent the 
formation of anti-F.VIII antibodies has also been attempted, 
with mixed results. Oral administration of purified F.VIII to 
newborn mice did not suppress induction of anti-F.VIII anti 
bodies (Kaplanet al. 2000. Semin. Thromb. Hemost. 26:173 
8). Oral administration of purified F.VIII to one of three 
patients with acquired hemophilia did reduce the amount of 
anti-F.VIII antibodies (Lindgren et al. 2000. Thromb. Hae 
most. 83:632-3). However, there are no teachings that oral 
administration of clotting factors alone can be used to treat 
hemophilia which is caused by inadequate expression of a 
clotting factor. 
Attempts to induce stable production of the missing clot 
ting factors by gene therapy using injections of transfected 
myoblasts have also been hampered by the host immune 
system which, not being tolerant of the missing factor, gen 
erates a strong rejection response when introduced (Fields et 
al. 2000. Mol. Ther. 3:225-35). Thus, inhibitory antibodies to 
the factors and vigorous T cell responses to the genetically 
transfected cells are major hurdles to successful treatment of 
hemophilia. 
Another disadvantage to introduction of a foreign gene 
through the use of a viral vector, is the possibility of an 
elicited immune response against the vector and/or the trans 
gene product. For example, intramuscular (i.m.) injection of 
an adenoviral vector expressing human F.IX into the hind 
limbs of hemophiliac mice results in a CTL response against 
FIX, and destruction of the transduced cells, whereas i.m. 
injection of a less immunogenic vector (adeno-associated 
virus, AAV) expressing human F.IX results in long-term per 
sistence of the transduced cells and an absence of CTL to FIX 
(Roberts. 1997. Inhibitors and their management. In Hemo 
philia & other inherited bleeding disorders, Rizza & Lowe, 
eds., WB Saunders Company Ltd., London, p. 365.). How 
ever, in both cases formation of antibodies neutralizes F.IX 
activity. The same problem exists in the canine model of 
hemophilia B, where anti-FIX antibodies neutralize F.IX 
activity after gene therapy with F.IX (Evans et al. 1989. Proc. 
Natl. Acad. Sci. U.S.A. 86:10095-9; Mauser et al. 1996. 
US 7,867,974 B2 
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Blood. 88:3451-5; Herzogetal. 1999. Nat. Med. 5:56-63; and 
Kay et al. 2000. Nat. Genet. 24:257-261). 
SUMMARY OF THE DISCLOSURE 
Although potentially large amounts of functional protein 
can be obtained from F.IX pigs, the current teaching has been 
to purify the factor from the milk, and Subsequently admin 
ister it intravenously (i.v.) to a hemophiliac patient. However, 
it would be advantageous if the protein could be delivered 
orally, as oral administration is more easily handled than 
injection, and may eliminate the need for protein purification. 
In addition, it would be beneficial if oral tolerance to clotting 
factors could be induced by oral administration of the clotting 
factor. 
Disclosed herein is a method for treating an antigen-defi 
ciency disease by orally administering a therapeutically 
effective amount of the deficient antigen. In one non-limiting 
example, the method is a method for increasing hemostasis in 
a Subject having a hemophilia caused by inadequate expres 
sion of a clotting factor, by orally administering a therapeu 
tically effective amount of a clotting factor other than in a 
liposome. In another example, the method is a method for 
decreasing the symptoms associated with Gaucher disease 
(such as decreasing hepatosplenomegaly and improving bone 
marrow involvement), in a subject having Gaucher disease 
caused by decreased expression of acid beta-glucosidase, by 
orally administering a therapeutically effective amount of a 
acid beta-glucosidase. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A is a dot-plot comparing the footpad Swelling in 
mice fed OVA prior to injection (0.110 mg OVA) with control 
mice not fed OVA prior to injection (0 mg OVA). 
FIG. 1B shows three dot-plots comparing the amount of 
IL-4, TGF-B, and IFN-Y production in mice fed OVA prior to 
injection, with control mice not fed OVA (water) prior to 
injection. 
FIG. 1C is a graph comparing the amount of T-cell prolif 
eration in mice fed OVA prior to injection (0.001-10 mg OVA) 
with control mice not fed OVA prior to injection (0 mg OVA). 
FIGS. 2A and 2B are graphs comparing the amount of 
T-cell proliferation in (A) normal and (B) hemophilia B mice 
fed human F.IX prior to injection, with control mice not fed 
human F.IX prior to injection. 
FIG. 2C is a graph comparing the level of IgA produced in 
F.IX-fed hemophilia B mice to unfed normal mice. 
FIGS. 3A and 3B are dot plots showing (A) IgG1 and (B) 
IgG2a antibody responses to hFIX. 
FIG. 4 is a dot plot showing that orally tolerized hemophilia 
B mice show little evidence of inhibitors, as their bleeding 
times are only slightly longer than those of infused mice that 
had not been immunized. 
FIGS. 5A and 5B are graphs comparing the proliferative 
response against sheep casein, in lambs fed (A) sheep milk or 
(B) cow milk. 
FIG.5C is a dot plot comparing the serum IgG titer to sheep 
casein in lambs raised on sheep milk compared to cow milk. 
FIGS. 6A and 6B are a graph and a dot plot, respectively, 
showing that oral feeding of transgenic pig milk containing 
F.IX results in the presence of F.IX in the blood. 
FIG. 7A is a dot plot showing that orally administered F.IX 
remains functional, and corrects the bleeding defect in hemo 
philia B mice. 
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FIG. 7B is a graph showing that orally administered F.IX 
remains functional, and corrects the bleeding defect in hemo 
philia B mice fed F.IX milk for 2 months. 
FIGS. 8A and 8B are dot plots showing that orally admin 
istered F.VIII remains functional, whether administered in 
water or in cow's milk. 
FIG. 8C is a dot plot showing that immunization following 
oral administration of F.VIII does not inhibit F.VIII fed sub 
sequent to the immunization. 
FIG. 8D is a dot plot showing IgG1 and IgG2a antibody 
responses to hF.VIII. 
FIGS. 9A and 9B are graphs comparing the T cell response 
in mice fed FIX in water or milk showing that oral adminis 
tration of F.IX can beachieved whether administered in water 
or in milk, but that it is more effective if given in milk. 
DETAILED DESCRIPTION OF SEVERAL 
EMBODIMENTS 
Abbreviations and Terms 
The following explanations of terms and methods are pro 
vided to better describe the present disclosure and to guide 
those of ordinary skill in the art in the practice of the present 
disclosure. As used herein and in the appended claims, the 
singular forms “a” or “an or “the include plural references 
unless the context clearly dictates otherwise. For example, 
reference to “a protein’ includes a plurality of such proteins 
and reference to “the antibody' includes reference to one or 
more antibodies and equivalents thereof known to those 
skilled in the art, and so forth. 
Unless explained otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood to one of ordinary skill in the art to which this 
disclosure belongs. 
Antigen: A Substance capable of being the target of induc 
ing a specific immune response. 
Antigen-Deficiency Disease: A disease in which a subject 
has an antigen deficiency, such as a protein, which causes the 
disease. Examples of antigen-deficiency diseases include, but 
are not limited to clotting disorders such as hemophilia A and 
B (caused by a deficiency of clotting factor VIII and IX, 
respectively), Von Willebrand’s disease (caused by a moder 
ate-to-severe factor VIII deficiency, low-levels of factor VIII 
related antigen, and insufficient von Willebrand factor); and 
diabetes (caused by a deficiency of insulin). 
Other examples of antigen deficiency diseases include, but 
are not limited to: Strokes or heart attacks (deficiency of tissue 
plasminogen activator); emphysema (deficiency of alpha-1- 
antitrypsin); Gaucher disease (deficiency of B-glucosidase), 
Pompe’s disease (deficiency of alpha-1,4-glucosidase); pur 
pura fulminans neonatalis, warfin-induced skin necrosis, hep 
arin-induced thrombocytopenia, septic shock, and for fibrin 
olytic therapy (deficiency of protein C) (also see U.S. Pat. No. 
5,589,604). 
In a particular embodiment, the treatment of such diseases 
can be achieved by orally administering the deficient antigen 
to a subject having the disease. 
Anti-immune therapy: Administration of agents to a Sub 
60 ject having an autoimmune disease to reduce the immune 
65 
response against normal body tissue while leaving intact the 
immune response against micro-organisms and abnormal tis 
Sues. Examples of agents used to reduce the immune response 
include, but are not limited to: corticosteroids and immuno 
Suppressant medications (including prednisolone, cyclophos 
phamide or azathioprine) or cytotoxic agents such as cyto 
toxan or methotrexate. 
US 7,867,974 B2 
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Activated partial thromboplastin time (APTT) Assay: An 
assay that measures the time it takes plasma to clot. APTT is 
the period required for clot formation in recalcified blood 
plasma after contact activation and the addition of platelet 
Substitutes (e.g., brain cephalin or similar phospholipids). In 
normal individuals, the APTT is about 30-40 seconds, and the 
PTT (therapeutic level) is 60 to 70 seconds. A prolonged 
APPT can indicate a deficiency of a number of clotting factors 
including Factors XII, XI, IX, VIII, X, V, and II, and fibrino 
gen. 
Bleeding Time Assay: An assay used to measure the 
amount of time it takes for a subjects blood to clot. A blood 
pressure cuff is placed on the upper arm and inflated. Two 
incisions are made on the lower arm. These are about 10 mm 
(less than /2 inch) long and 1 mm deep (just deep enough to 
cause minimal bleeding). The blood pressure cuff is immedi 
ately deflated. Blotting paper is touched to the cuts every 30 
seconds until the bleeding stops. The length of time it takes 
for the cuts to stop bleeding is recorded. 
In normal, non-hemophiliacs, bleeding stops within about 
one to ten minutes and may vary from lab to lab, depending on 
how the assay is measured. In contrast, severe hemophiliacs 
having less than 1% of normal levels of the appropriate clot 
ting factor have a whole blood clotting time of greater than 60 
minutes. 
In mice, the bleeding time is assayed by transecting the tip 
of the tail and periodically touching a blotting paper until a 
clot is formed at the tip of the tail. Normal bleeding time is 
between 2-4 minutes. In contrast, hemophiliac mice having 
less than 1% of normal levels of the appropriate clotting factor 
have a bleeding time of greater than 15 minutes (see FIGS. 
7A, 7B, 8A and 8B). 
cDNA (complementary DNA): A piece of DNA lacking 
internal, non-coding segments (introns) and regulatory 
sequences which determine transcription. cDNA can be Syn 
thesized in the laboratory by reverse transcription from mes 
senger RNA extracted from cells. 
Chemical synthesis: An artificial means by which one can 
make a protein or peptide. A synthetic protein or peptide is 
one made by Such artificial means. 
Clotting disorder: A disease resulting in a defect in hemo 
Stasis in a Subject. In one embodiment, it is a disease of the 
blood clotting (coagulation) system in which bleeding is pro 
longed due to inadequate clotting factors in the blood, for 
example inadequate expression of the clotting factor, Such as 
inadequate expression due to a genetic abnormality. Normal 
blood hemostasis is a complex process involving as many as 
20 different plasma proteins, known as clotting factors. Nor 
mally, a complex chemical process occurs using these clot 
ting factors to form a substance called fibrin that stops bleed 
ing. When certain coagulation factors are deficient or 
missing, the process does not occur normally. Bleeding prob 
lems can range from mild to severe. 
Some bleeding disorders are present at birth and in some 
instances are inherited disorders. Specific examples include, 
but are not limited to: hemophilia A, hemophilia B, protein C 
deficiency, and Von Willebrand’s disease. Some bleeding dis 
orders are developed during certain illnesses (such as vitamin 
K deficiency, severe liver disease), or treatments (such as use 
of anticoagulant drugs or prolonged use of antibiotics). 
Clotting factor: Includes any protein which promotes 
proper hemostasis. In one embodiment, a clotting factor is 
factor VIII (F.VIII) or factor IX (F.IX), or a variant or frag 
ment thereof which retains its hemostatic activity, for 
example as measured using an APTT assay or a bleeding time 
assay. In another embodiment, when orally administered in a 
therapeutically effective amount, the clotting factor increases 
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hemostasis in a Subject Suffering from a clotting disorder, 
Such as hemophilia. In a particular embodiment, a clotting 
factor is a recombinant clotting factor, wherein expression of 
a DNA encoding the clotting factor in a mammal results in the 
presence of the recombinant clotting factor protein in the milk 
of the transgenic mammal. 
Comprises: A term that means “including.” For example, 
“comprising A or B' means including A or B, or both A and 
B, unless clearly indicated otherwise. 
Deletion: The removal of a sequence of a nucleic acid, for 
example DNA, the regions on either side being joined 
together. 
DNA: Deoxyribonucleic acid. DNA is a long chain poly 
mer which comprises the genetic material of most living 
organisms (some viruses have genes comprising ribonucleic 
acid, RNA). The repeating units in DNA polymers are four 
different nucleotides, each of which comprises one of the four 
bases, adenine, guanine, cytosine and thymine bound to a 
deoxyribose Sugar to which a phosphate group is attached. 
Triplets of nucleotides, referred to as codons, in DNA mol 
ecules code for amino acid in a polypeptide. The term codon 
is also used for the corresponding (and complementary) 
sequences of three nucleotides in the mRNA into which the 
DNA sequence is transcribed. 
Enhance: To improve the quality, amount, or strength of 
Something. In one embodiment, a therapy enhances or 
increases hemostasis in a Subject (Such as a hemophiliac) if 
the subject is more effective at blood clotting (for example, 
their blood clotting time decreases). Such enhancement can 
be measured using the methods disclosed herein, for example 
determining the bleeding time of a subject using an APTT or 
bleeding time assay. 
Factor VIII (F.VIII): F.VIII is a protein required for the 
efficient clotting of blood, and functions in coagulation as a 
cofactor in the activation of factor X by factor IX. A concen 
tration of about 100 ng/ml for F.VIII in the blood is consid 
ered in the normal range. Deficiency of F.VIII is associated 
with hemophilia A, and severe forms of the disease can result 
when a subject has less than about 1% of the normal amount 
of F.VIII (i.e. less than about 1 ng of F.VIII per ml of blood). 
F.VIII is synthesized as a 2351 amino acid single chain pre 
cursor protein, which is proteolytically processed. The 
human factor VIII gene (186,000 base-pairs) consists of 26 
exons ranging in size from 69 to 3,106 bp and introns as large 
as 32.4 kilobases (kb). Examples of F.VIII nucleic acid and 
protein sequences, including variants and fragments thereof, 
and sequences from different organisms, are publicly avail 
able on Genbank (for example see Accession Nos: KO1740, 
M14113, and E00527 (human); AF016234 (canine); and 
L05573 (mouse)). 
Gaucher Disease: An autosomal-recessive disorder that 
results from defective activity of acid -glucosidase. Disease 
variants are classified based on the absence or presence and 
severity of neuronopathic involvement. Enzyme therapy is 
currently the treatment of choice in significantly affected 
patients. For example, cereZyme, a recombinantly produced 
mannose-terminated (macrophage-targeted) acid B-glucosi 
dase, is currently used to diminish hepatosplenomegaly and 
improve bone marrow involvement and hematologic find 
ings. However, it is possible that oral administration off-glu 
cosidase using the methods disclosed herein, can be used to 
alleviate one or more symptoms associated with Gaucher 
disease described below. 
Type 2 Gaucher disease is a rare, severe CNS disease that 
leads to death by 2 years of age. 
Type 3 Gaucher disease has highly variable manifestations 
in the CNS and viscera. It can present in early childhood with 
US 7,867,974 B2 
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rapidly progressive, massive visceral disease and slowly pro 
gressive to static CNS involvement; in adolescence with 
dementia; or in early adulthood with rapidly progressive, 
uncontrollable myoclonic seizures and mild visceral disease. 
Visceral disease in type 3 is nearly identical to that in type 1, 
but is generally more severe. Early CNS findings may be 
limited to defects in lateral gaze tracking, which may remain 
static for decades. Mental retardation can be slowly progres 
sive or static. 
Type 1 Gaucher disease is a highly variable nonneurono 
pathic disease. Younger patients tend to have a greater degree 
of hepatosplenomegaly and accompanying blood cytopenias. 
Older patients have a greater tendency for chronic bone dis 
ease. Hepatosplenomegaly occurs in virtually all symptom 
atic patients and can be minor or massive. Accompanying 
anemia and thrombocytopenia are variable and not linearly 
related to liver or spleen volume. Severe liver dysfunction is 
unusual, though minor liver function abnormalities are com 
mon. Splenic infarctions can resemble an acute abdomen. 
Pulmonary hypertension and alveolar Gaucher cell accumu 
lation are uncommon, but life-threatening. 
Though it is more common in adult patients, clinically 
evident skeletal disease in children can be devastating, result 
ing in massive destruction of the axial and peripheral skel 
eton. All patients with Gaucher disease have non-uniform 
infiltration of bone marrow by lipid-laden macrophages, 
termed Gaucher cells. This can lead to marrow packing with 
Subsequent infarction, ischemia, necrosis, and cortical bone 
destruction. Bone marrow involvement spreads from proxi 
mal to distal in the limbs and can involve the axial skeleton 
extensively, causing vertebral collapse. In addition to bone 
marrow involvement, bone remodeling is defective, with loss 
of total bone calcium leading to osteopenia, osteonecrosis, 
avascular infarction, and vertebral compression fractures and 
spinal cord involvement. Aseptic necrosis of the femoral head 
is common, as is fracture of the femoral neck. 
Affected patients experience chronic, ill-defined bone pain 
that can be debilitating. Some patients have one or more 
“bone crises' in their lifetimes that are associated with local 
ized, excruciating pain, and, on occasion, local erythema, 
fever, and leukocytosis. Any bone can be involved, though the 
femurs and vertebral bodies are affected most often. These 
crises represent acute infarctions of bone, as evidenced in 
nuclear scans by localized absent uptake of pyrophosphate 
agents. X-rays are usually negative initially but may show 
lytic lesions 4 to 6 months after the acute phase. 
The diagnosis of Gaucher disease is established by dem 
onstrating decreased acid B-glucosidase activity (0 to 20% of 
normal) in nucleated cells. The enzyme is not present in 
bodily fluids. The sensitivity of enzyme testing is poor for 
detecting heterozygous carriers; molecular testing is pre 
ferred when the mutations are known. Four common muta 
tions account for ~90 to 95% of the mutations in affected 
patients: N370S (1226G), 84GG (a G insertion at cDNA 
position 84), L444P (1448C), and IVS-2 (an intron 2 splice junction mutation). Genotype/phenotype studies indicate a 
significant correlation, though not absolute, between disease 
type and severity and the acid B-glucosidase genotype. 
Factor IX (F.IX): F.IX is a vitamin K-dependent protein 
required for the efficient clotting of blood, and functions in 
coagulation as an activator of factor X. A concentration of 
about 1-5 lug/ml of F.IX in the blood is considered in the 
normal range. Deficiency of F.IX is associated with hemo 
philia B, and severe cases result when the concentration of 
FIX is less than about 1% of the normal concentration of F.IX 
(i.e. less than about 0.01-0.05 ug F.IX per ml of blood). 
Canine F.IX possesses 86% identity at the amino-acid level 
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with human F.IX (Evans et al. 1989. Blood 74:207-12). F.IX 
nucleic acid and protein sequences, including variants and 
fragments thereof, and sequences from different organisms, 
are publicly available (for example see Kurachi et al., 1982. 
Proc. Natl. Acad. Sci. U.S.A. 79(21):6461-4: Genbank Acces 
sion Nos: JOO136, XM 045316, KO2402, J00137, and 
M11309 (human) and M21757 and M33826 (canine)). 
Hemophilia: A blood coagulation disorder caused by a 
deficient clotting factor activity, which decreases hemostasis. 
Severe forms result when the concentration of clotting factor 
is less than about 1% of the normal concentration of the 
clotting factor in a normal Subject. In some subjects, hemo 
philia is due to a genetic mutation which results in impaired 
expression of a clotting factor. In others, hemophilia is an 
auto-immune disorder, referred to as acquired hemophilia, in 
which the antibodies which are generated against a clotting 
factor in a Subject result in decreased hemostasis. 
Hemophilia A results from a deficiency of functional clot 
ting factor VIII (F.VIII), while hemophilia B results from a 
deficiency of functional clotting factor IX (F.IX). These con 
ditions which are due to a genetic mutation are caused by an 
inherited sex-linked recessive trait with the defective gene 
located on the X chromosome, and this disease is therefore 
generally found only in males. The severity of symptoms can 
vary with this disease, and the severe forms become apparent 
early on. Bleeding is the hallmark of the disease and typically 
occurs when a male infant is circumcised. Additional bleed 
ing manifestations make their appearance when the infant 
becomes mobile. Mild cases may go unnoticed until later in 
life when they occur in response to Surgery or trauma. Internal 
bleeding may happen anywhere, and bleeding into joints is 
COO. 
Hemophiliac: A Subject having a hemophilia. 
Hemostasis: Arrest of bleeding blood by blood clot forma 
tion. When hemostasis is increased, it is increased relative to 
hemostasis in a Subject prior to orally administering a thera 
peutically effective amount of the appropriate clotting factor 
to the Subject. In one embodiment, when hemostasis 
increases in a Subject with hemophilia, the blood clotting time 
decreases. Blood clotting time is the length of time it takes for 
peripheral blood to clot using an activated partial thrombo 
plastintime assay (APTT, see EXAMPLE 9) or by measuring 
bleeding time (see above and EXAMPLE 5). In a particular 
embodiment, the blood clotting time decreases by at least 
50%, for example at least 60%, at least 70%, at least 75%, at 
least 80%, at least 90%, at least 95%, at least 98%, at least 
99% or even about 100% (i.e. the blood clotting time is 
similar to what is observed for a normal subject) when com 
pared to the blood clotting time of the subject prior to orally 
administering to the subject a therapeutically effective 
amount of the appropriate clotting factor. In yet another 
embodiment, the blood clotting time in the affected subject is 
corrected to about 90% of a normal subject, for example to 
about 95%, for example about 100%, after oral administra 
tion of a therapeutically effective amount of the appropriate 
clotting factor. 
Impaired Expression: Decreased expression of a DNA or 
protein resulting in a deficiency of the protein in a Subject. 
Such a protein deficiency may cause disease in the Subject. 
Isolated: An isolated nucleic acid has been substantially 
separated or purified away from other nucleic acid sequences 
in the cell of the organism in which the nucleic acid naturally 
occurs, i.e., other chromosomal and extrachromosomal DNA 
and RNA. The term "isolated thus encompasses nucleic 
acids purified by standard nucleic acid purification methods. 
US 7,867,974 B2 
The term also embraces nucleic acids prepared by recombi 
nant expression in a host cell as well as chemically synthe 
sized nucleic acids. 
Liposome: A closed, solvent-filled vesicle bounded by a 
single bilayer of phospholipids, which is impermeable to 
many Substances. In one embodiment, a liposome has the 
properties described in U.S. Pat. No. 4,348,384 to Horikoshi 
et al. (herein incorporated by reference). 
Mammal: This term includes both human and non-human 
mammals. Similarly, the terms “patient,” “subject,” and 
“individual' includes both human and veterinary subjects. 
Examples of mammals include, but are not limited to: 
humans, pigs, cows, goats, cats, dogs, rabbits and mice. 
Normal Cells: Non-disease cells. In one embodiment, nor 
mal cells are cells obtained from a healthy subject, for 
example as compared to a hemophilic or diabetic Subject. 
Normal Subject: A subject who does not have an antigen 
deficiency disease. For example, a subject who does not have 
hemophilia A or B. 
Oligonucleotide: A linear polynucleotide sequence of up to 
about 200 nucleotide bases in length, for example a poly 
nucleotide (such as DNA or RNA) which is at least about 6 
nucleotides, for example at least 15, 50, 100 or 200 nucle 
otides long. 
Operably linked: A first nucleic acid sequence is operably 
linked with a second nucleic acid sequence when the first 
nucleic acid sequence is placed in a functional relationship 
with the second nucleic acid sequence. For instance, a pro 
moter is operably linked to a coding sequence if the promoter 
affects the transcription or expression of the coding sequence. 
Generally, operably linked DNA sequences are contiguous 
and, where necessary to join two protein coding regions, in 
the same reading frame. 
ORF (open reading frame): A series of nucleotide triplets 
(codons) coding for amino acids without any termination 
codons. These sequences are usually translatable into a pep 
tide. 
Oral administration: A method of delivering an agent to a 
Subject by mouth. In one embodiment, oral administration is 
achieved by feeding the agent to the Subject. In a particular 
embodiment, the agent is an antigen, such as a protein, for 
example F.VIII or F.IX. The agent can be delivered with one 
or more pharmaceutically acceptable carriers which are not 
liposomes. In addition, the agent and one or more therapeu 
tically effective pharmaceutical compounds can be adminis 
tered concurrently or separately. 
Oral tolerance: A method of downregulating an immune 
response in a Subject by orally administering an antigen (i.e. 
by feeding) to the subject. Oral tolerance is characterized by 
decreased levels of systemic antibody production, as well as 
decreased delayed type hypersensitivity responses (DTH), T 
cell proliferation, cytotoxic responses and graft rejection (Al 
pan et al. 2001. J. Immunol. 166:4843-52; Chen et al. 1995. 
Nature 376:177-80; Weiner. 1997. Imm. Today: 7:335-44: 
Sayegh et al. 1992. Transplantation. 53:163-6). 
The tolerogenic effect due to administration of high doses 
oral antigen is deletion of antigen-specific T cells by apopto 
sis (Weiner. 1997. Imm. Today. 7:335-44). Administration of 
low doses of oral antigen induces a Switch in effector class 
such that Th1 type responses (DTH, cytotoxicity, graft rejec 
tion and complement fixing antibodies) are Supplanted by 
Th3 type responses (the production of IL-4, IL 10, TGF-3 and, 
occasionally, secretory IgA) (Weiner. 1997. Imm. Today. 
7:335-44). Low dose oral tolerance reduces the severity of 
EAE (Fields et al. 2000. Molecular Therapy. 3:225-35) and 
enables the acceptance of foreign transplants. 
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Promoter: An array of nucleic acid control sequences 
which direct transcription of a nucleic acid. A promoter 
includes necessary nucleic acid sequences near the start site 
of transcription, Such as, in the case of a polymerase II type 
promoter, a TATA element. A promoter also optionally 
includes distal enhancer or repressor elements which can be 
located as much as several thousand base pairs from the start 
site of transcription. 
Purified: The term purified does not require absolute 
purity; rather, it is intended as a relative term. Thus, for 
example, a purified clotting factor preparation is one in which 
the factor is more pure than the factor in its natural environ 
ment within a cell. For example, a preparation of a clotting 
factor protein is purified if the protein represents at least 50%, 
for example at least 70%, of the total protein content of the 
preparation. Methods for purification of proteins and nucleic 
acids are well known in the art. Examples of methods that can 
be used to purify an antigen, Such as a clotting factor include, 
but are not limited to the methods disclosed in Sambrooketal. 
(Molecular Cloning. A Laboratory Manual, Cold Spring 
Harbor, N.Y., 1989, Ch. 17); U.S. Pat. No. 6,005,082 to 
Smeds; EP 0294.910 to van Ooyen et al.: 
Recombinant: A recombinant nucleic acid is one that has a 
sequence that is not naturally occurring or has a sequence that 
is made by an artificial combination of two otherwise sepa 
rated segments of sequence. This artificial combination is 
often accomplished by chemical synthesis or, more com 
monly, by the artificial manipulation of isolated segments of 
nucleic acids, e.g., by genetic engineering techniques. A 
recombinant protein is one that results from expressing a 
recombinant nucleic acid encoding the protein. 
RT: Room temperature 
Sample: Biological samples containing genomic DNA, 
cDNA, RNA, or protein obtained from the cells of a subject, 
Such as those present in peripheral blood, urine, saliva, tissue 
biopsy, Surgical specimen, fine needle aspriates, amniocente 
sis samples and autopsy material. 
Sequence identity/similarity: The identity/similarity 
between two or more nucleic acid sequences, or two or more 
amino acid sequences, is expressed in terms of the identity or 
similarity between the sequences. Sequence identity can be 
measured in terms of percentage identity; the higher the per 
centage, the more identical the sequences are. Sequence simi 
larity can be measured in terms of percentage similarity 
(which takes into account conservative amino acid substitu 
tions); the higher the percentage, the more similar the 
Sequences are. 
Methods of alignment of sequences for comparison are 
well known in the art. Various programs and alignment algo 
rithms are described in: Smith & Waterman, Adv. Appl. Math. 
2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 
1970: Pearson & Lipman, Proc. Natl. Acad. Sci. 85:2444, 
1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & 
Sharp, CABIOS 5:151-3, 1939; Corpet et al., Nuc. Acids Res. 
16:10881-90, 1988; Huang et al. Computer Appls. in the 
Biosciences 8, 155-65, 1992; and Pearson et al., Meth. Mol. 
Bio. 24:307-31, 1994. Altschul et al., J. Mol. Biol. 215:403 
10, 1990, presents a detailed consideration of sequence align 
ment methods and homology calculations. 
The NCBI Basic Local Alignment Search Tool (BLAST) 
(Altschulet al., J. Mol. Biol. 215:403-10, 1990) is available 
from several sources, including the National Center for Bio 
logical Information (NCBI, National Library of Medicine, 
Building 38A, Room 8N805, Bethesda, Md. 20894) and on 
the Internet, for use in connection with the sequence analysis 
programs blastp, blastin, blastX, thlastnandthlastX. Additional 
information can be found at the NCBI web site. 
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For comparisons of amino acid sequences of greater than 
about 30 amino acids, the Blast 2 sequences function is 
employed using the default BLOSUM62 matrix set to default 
parameters, (gap existence cost of 11, and a per residue gap 
cost of 1). When aligning short peptides (fewer than around 
30 amino acids), the alignment should be performed using the 
Blast 2 sequences function, employing the PAM30 matrix set 
to default parameters (open gap 9. extension gap 1 penalties). 
Proteins with even greater similarity to the reference 
sequence will show increasing percentage identities when 
assessed by this method, such as at least 70%, 75%, 80%, 
85%, 90%. 95%, or even 99% sequence identity. When less 
than the entire sequence is being compared for sequence 
identity, homologs will typically possess at least 75% 
sequence identity over short windows of 10-20 amino acids, 
and can possess sequence identities of at least 85%, 90%, 
95% or 98% depending on their identity to the reference 
sequence. Methods for determining sequence identity over 
such short windows are described at the NCBI web site. 
Protein homologs are typically characterized by posses 
sion of at least 70%, such as at least 75%, 80%, 85%, 90%, 
95% or even 98% sequence identity, counted over the full 
length alignment with the amino acid sequence using the 
NCBI, Basic Blast 2.0 gapped blastp with databases such as 
the nr or Swissprot database. Queries searched with the blastin 
program are filtered with DUST (Hancock and Armstrong, 
1994, Comput. Appl. Biosci. 10:67-70). Other programs use 
SEG. 
One of skill in the art will appreciate that these sequence 
identity ranges are provided for guidance only; it is possible 
that strongly significant homologs could be obtained that fall 
outside the ranges provided. Provided herein are the peptide 
homologs described above, as well as nucleic acid molecules 
that encode Such homologs. 
Nucleic acid sequences that do not show a high degree of 
identity may nevertheless encode identical or similar (con 
served) amino acid sequences, due to the degeneracy of the 
genetic code. Changes in a nucleic acid sequence can be made 
using this degeneracy to produce multiple nucleic acid mol 
ecules that all encode substantially the same protein. Such 
homologous peptides can, for example, possess at least 75%, 
80%, 90%, 95%, 98%, or 99% sequence identity determined 
by this method. When less than the entire sequence is being 
compared for sequence identity, homologs can, for example, 
possess at least 75%, 85%, 90%. 95%, 98% or 99% sequence 
identity over short windows of 10-20 amino acids. Methods 
for determining sequence identity over Such short windows 
can be found at the NCBI web site. One of skill in the art will 
appreciate that these sequence identity ranges are provided 
for guidance only; it is possible that significant homologs or 
other variants can be obtained that fall outside the ranges 
provided. 
Subject: Living multicellular vertebrate organisms, a cat 
egory which includes, both human and veterinary Subjects for 
example, mammals, rodents, and birds. 
Therapeutically Effective Amount: An amount sufficient to 
achieve a desired biological effect, for example an amount 
that is effective to increase hemostasis. In particular 
examples, it is a concentration of clotting factor. Such as 
F.VIII or F.IX, effective to increase hemostasis, such as in a 
Subject to whom it is administered, such as a hemophiliac. In 
other examples, it is an amount effective to increase hemo 
Stasis by more than a desired amount. 
In one embodiment, the therapeutically effective amount 
also includes a quantity of clotting factor (such as a clotting 
factor protein or nucleic acid) sufficient to achieve a desired 
effect in a subject being treated. For instance, these can be an 
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amount necessary to improve signs and/or symptoms a dis 
ease Such as hemophilia, for example by increasing hemosta 
S1S. 
An effective amount of a clotting factor can be adminis 
tered in a single dose, or in several doses, for example daily, 
during a course of treatment. However, the effective amount 
of clotting factor will be dependent on the source of clotting 
factor administered (i.e. clotting factor isolated from a blood 
sample versus recombinant clotting factor expressed in milk), 
the subject being treated, the severity and type of the condi 
tion being treated, and the manner of administration clotting 
factor. For example, a therapeutically effective amount of 
clotting factor can vary from about 0.01 mg/kg body weight to 
about 5 g/kg body weight, for example, at least 5 mg/kg daily, 
for example at least 50 mg/kg daily. In other embodiment, it 
is a concentration of F.VIII, when orally administered, which 
results in a blood concentration of greater than about 1 ng 
F.VIII per ml blood, for example greater than about 10 ng per 
ml, for example about 100 ng per ml. In yet another embodi 
ment, it is a concentration of F.IX, when orally administered, 
which results in a blood concentration of greater than about 
0.01-0.05 ug F.IX per ml blood, for example greater than 
about 0.1-0.5ug per ml, for example about 1-5ug per ml. 
The methods disclosed herein have equal application in 
medical and Veterinary settings. Therefore, the general term 
“subject being treated is understood to include all animals 
(e.g. humans, apes, dogs, cats, horses, and cows) that require 
an increase in the desired biological effect, Such as enhanced 
hemostasis Susceptible to clotting factor-mediated modula 
tion. 
Therapeutically effective dose: A dose of antigen sufficient 
to increase the amount of that antigen in a subject to whom it 
is administered, resulting in a regression of a pathological 
condition, or which is capable of relieving signs or symptoms 
caused by the condition. In a particular embodiment, it is a 
dose of clotting factor Sufficient to increase hemostasis in a 
hemophiliac. 
Transformed: A transformed cell is a cell into which has 
been introduced a nucleic acid molecule by molecular biol 
ogy techniques. As used herein, the term transformation 
encompasses all techniques by which a nucleic acid molecule 
might be introduced into such a cell, including transfection 
with viral vectors, transformation with plasmid vectors, and 
introduction of naked DNA by electroporation, lipofection, 
and particle gun acceleration. 
Transgenic Cell: Transformed cells which contain foreign, 
non-native DNA. 
Transgenic mammal: Transformed mammals which con 
tain foreign, non-native DNA. In one embodiment, the non 
native DNA is an antigen, such as human F.VIII or human 
F.IX. In a particular embodiment, a transgenic mammal 
expresses a recombinant clotting factor in its milk. In yet 
another embodiment, the transgenic animal is a pig express 
ing recombinant human F.VIII or F.IX in its milk. One skilled 
in the art will understand that any mammal can be used, 
including, but not limited to pigs, cows, goats, sheep, rats, 
mice, rabbits, dogs, cats, and primates. 
Variants or fragments or fusion proteins: The production of 
protein which is orally administered can be accomplished in 
a variety of ways (for example see EXAMPLES 15 and 16). 
DNA sequences which encode for a protein or fusion protein, 
or a fragment or variant of a protein (for example a fragment 
or variant having 80%, 90% or 95% sequence identity to a 
blood clotting factor) can be engineered to allow the protein 
to be expressed in eukaryotic cells or organisms, bacteria, 
insects, and/or plants. To obtain expression, the DNA 
sequence can be altered and operably linked to other regula 
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tory sequences. The final product, which contains the regula 
tory sequences and the therapeutic protein, is referred to as a 
vector. This vector can be introduced into eukaryotic, bacte 
ria, insect, and/or plant cells. Once inside the cell the vector 
allows the protein to be produced. 
A fusion antigen comprising a protein, such as F.VIII or 
FIX (or variants, polymorphisms, mutants, or fragments 
thereof) linked to other amino acid sequences that do not 
inhibit the desired activity of the protein, for example the 
ability to increase hemostasis. In one embodiment, the other 
amino acid sequences are no more than 10, 20, 30, or 50 
amino acid residues in length. 
One of ordinary skill in the art will appreciate that the DNA 
can be altered in numerous ways without affecting the bio 
logical activity of the encoded protein. For example, PCR can 
be used to produce variations in the DNA sequence which 
encodes an antigen. Such variants can be variants optimized 
for codon preference in a host cell used to express the protein, 
or other sequence changes that facilitate expression. 
Vector: A nucleic acid molecule as introduced into a host 
cell, thereby producing a transformed host cell. A vector can 
include nucleic acid sequences that permit it to replicate in the 
host cell. Such as an origin of replication. A vector can also 
include one or more selectable marker genes and other 
genetic elements known in the art. 
Additional definitions of terms commonly used in molecu 
lar genetics can be found in Benjamin Lewin, Genes V pub 
lished by Oxford University Press, 1994 (ISBN 0-19-854287 
9); Kendrew et al. (eds.). The Encyclopedia of Molecular 
Biology, published by Blackwell Science Ltd., 1994 (ISBN 
0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biol 
ogy and Biotechnology: a Comprehensive Desk Reference, 
published by VCH Publishers, Inc., 1995 (ISBN 1-56081 
569-8). 
Disclosed herein is a method for increasing hemostasis in a 
Subject having a hemophilia by orally administering to the 
Subject a therapeutically effective amount of a clotting factor 
not present in a liposome, Sufficient to induce oral tolerance 
and Supply exogenous clotting factor to the Subject. In one 
embodiment, hemophilia is a result of impaired expression of 
a clotting factor. In yet another embodiment, increasing 
hemostasis comprises decreasing blood clotting time. For 
example, blood clotting time can be decreased by at least 
50%, for example at least 60%, at least 70%, at least 80%, at 
least 85%, at least 90%, at least 95%, at least 98%, or even at 
least 99% compared to a blood clotting time of an untreated 
hemophilic subject. The blood clotting time can be measured 
using an activated partial thromboplastin time (APTT) assay 
or by a bleeding time assay. 
In another embodiment, the clotting factor is administered 
in absence of an anti-immune therapy. In a particular embodi 
ment, atherapeutically effective amount of a clotting factor is 
a daily dose of at least 5 mg of clotting factorper kg of subject, 
for example at least 50 mg of clotting factor per kg of subject. 
The clotting factor can be administered daily or every other 
day. The Subject to be treated can be a mammal, for example 
a human or dog. The hemophilia can be hemophilia A and the 
clotting factor F.VIII, or hemophilia B and the clotting factor 
F.IX. In one embodiment, a therapeutically effective amount 
of F.VIII is at least 5 mg of clotting factor per 1 kg of subject 
daily and a therapeutically effective amount of F.IX is at least 
50 mg of clotting factor per 1 kg of Subject daily. 
In a particular embodiment, oral administration is achieved 
by feeding the subject a therapeutically effective amount of 
the clotting factor. For example, the clotting factor can be a 
recombinant clotting factor present in milk of a transgenic 
mammal, which is fed to a hemophiliac. In one embodiment, 
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the clotting factor, such as F.IX, is present in milk obtained 
from a transgenic pig expressing the clotting factor, such as 
recombinant F.IX. The clotting factors can be present in at 
least one pharmaceutically effective carrier, such as water or 
milk. 
The methods disclosed herein can further include admin 
istering to a Subject an isolated recombinant nucleic acid 
molecule encoding a clotting factor, Such that the clotting 
factor is expressed in the Subject. 
Also disclosed herein is a method for increasing hemosta 
sis in a Subject having a hemophilia, which includes, and in 
Some examples consists of orally administering to the Subject 
a therapeutically effective amount of a clotting factor and at 
least one pharmaceutically acceptable carrier which is not a 
liposome. In other examples, the pharmaceutical composi 
tions disclosed herein (including clotting factors) can be 
administered in combination, or separately, with one or more 
other therapeutic treatments, such as other agents that 
increase hemostasis. 
A method is also disclosed for orally administering a 
recombinant clotting factor to a Subject for treatment of a 
hemophilia by orally administering milk containing recom 
binant clotting factor to the subject at a therapeutically effec 
tive amount Such that hemostasis in the Subject is increased, 
thereby treating the hemophilia. In one embodiment, the milk 
contains at least 2 g recombinant clotting factor/liter of milk. 
At this concentration, a 70kg human would drink about 0.175 
liters of milk daily to achieve an effective dose of about at 
least 5 mg/kg or about 1.75 liters of milk to achieve an 
effective dose of about at least 50 mg/kg. The milk can be 
obtained from a transgenic mammal. Such as a pig which 
expresses the clotting factor (or other therapeutic protein) in 
its milk. In a particular example, the milk can contain recom 
binant F.IX antigenata concentration of about 2 g per liter, for 
example about 2.5g per L., either expressed in the milk or 
exogenously added to the milk. 
Also disclosed herein is a method for orally administering 
a recombinant clotting factor to a Subject for treatment of a 
hemophilia by expressing the clotting factor in a mammal 
Such that the clotting factor is expressed in milk of the mam 
mal and orally administering the milk in which the clotting 
factor has been expressed to the Subject at a therapeutically 
effective amount such that blood clotting time in the subject is 
reduced, thereby treating the hemophilia. In a particular 
embodiment, the hemophilia is hemophilia B and the clotting 
factor is FIX. 
Further disclosed is a method for orally administering a 
recombinant F.IX protein to a subject for treatment of hemo 
philia B by orally administering milk containing recombinant 
F.IX protein at a therapeutically effective amount such that 
blood clotting time in the subject is reduced, thereby treating 
the hemophilia B. 
Also disclosed is a method of orally administering to a 
hemophiliac a therapeutically effective amount of a clotting 
factor protein Sufficient to induce oral tolerance to the clotting 
factor protein and Supply exogenous clotting factor protein to 
the hemophiliac, wherein the clotting factor protein is not 
presentina liposome, and wherein oral tolerance prepares the 
hemophiliac for in vivo expression of a clotting factor gene. 
In a particular embodiment, the clotting factor is F.VIII or 
F.IX. 
Disclosure of certain specific examples is not meant to 
exclude other embodiments. 
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EXAMPLE1 
Ovalbumin Oral Tolerance 
This example describes the methods used to induce oral 
tolerance in mice to ovalbumin (OVA) by first orally admin 
istering OVA prior to immunization with OVA. Similar meth 
ods can be used to test any antigen of interest. Such as F.VIII, 
F.IX, protein C, or insulin, in any animal/subject of interest. 
Normal B10 mice were fed OVA by adding the protein to 
their drinking water for eight days at concentrations of 0.02, 
0.2 or 2 mg/ml. The mice drank an average of 5.2 ml/mouse? 
day. Therefore, the doses were 0.1, 1.0 and 10 mg/mouse/day 
of OVA. Control mice only drank water. Two days after the 
last feeding, all mice were immunized with 50 lug OVA in 
complete Freund's adjuvant (CFA) (Sigma, St. Louis, Mo.) in 
the left footpad. Seven days later, footpad swelling was deter 
mined by measuring the thickness of the footpad. Measure 
ment of the right (un-injected) footpad served as an untreated 
control. The footpad Swelling responses were compared 
between injected, OVA-fed mice and injected, non-OVA fed 
control mice. As shown in FIG. 1A, the footpads of OVA-fed 
mice swelled less than those of the unfed group. 
To compare the amount of IL-4, TGF-B, and IFN-Y produc 
tion, mice were fed 0.1 mg OVA for 10 days, then immunized 
as described above. Seven days after immunization, lymph 
nodes draining the immunization site were harvested and 
cultured in vitro with 100 g/ml OVA. The culture was carried 
in 96 well round bottom plates, with 500,000 cells per well, 
for four days. For the last 8 hours of the culture, cells were 
pulsed with tritiated thymidine to assay for proliferation 
using a beta plate cell harvester. For IL-4 and IFN-y, super 
natants were assayed at day four. For TGF-B, after four days 
in culture, cells were washed, restimulated with APC and 
OVA in serum-free medium, and Supernatants assayed at day 
three. ELISA assays were performed using commercially 
available kits from Endogen (Rockford, Ill.), according to the 
manufacturers instructions. As shown in FIG. 1B, OVA-fed 
mice made high levels of IL-4 and TGF-B, but low levels of 
IFN-Y compared to mice in the unfed group. 
To compare the amount of T-cell proliferation, mice were 
fed doses of OVA ranging from 0.001-10 mg every-other day 
for five feeds and immunized with 50 ug OVA in CFA. Seven 
days after immunization, lymph nodes draining the immuni 
zation site were harvested by surgical dissection. CD4 T-cells 
were purified from the lymph nodes and cultured in vitro with 
irradiated spleen cells and a graded concentration of OVA as 
described above. As shown in FIG. 1C, T cells in the draining 
lymph nodes of OVA-fed mice proliferated less than those 
mice in the unfed group. Since T cells in lymph nodes prolif 
erate in response to regional antigenic stimulation, the reduc 
tion in T cell proliferation was a measure of decreased anti 
genic stimulation from OVA injection in the footpad. 
EXAMPLE 2 
Factor IX Oral Tolerance 
This example describes experiments in which mice devel 
oped oral tolerance to F.IX by orally administering F.IX prior 
to immunization with F.IX, using the methods described in 
EXAMPLE 1. 
Briefly, normal B10. A mice (F.IX -/+) or hemophilia B 
mice (F.IX -/-) were fed transgenic human F.IX (hFIX) in 
pig milk (see EXAMPLE 5) or control pig milk (no hF.IX) 
every other day for three weeks. Individual mice drank about 
4 ml (10 ugh F.IX/day/mouse) of the milk at each time. Two 
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days after the last feeding, all mice were immunized with 50 
ug human F.IX emulsified in CPA at the base of the tail. Eight 
days later, the amount of T cell proliferation was determined 
by culturing T-cells from the lymph nodes with graded con 
centrations of human F.IX (purified from the transgenic pig 
milk) for four days using the methods described in 
EXAMPLE 1. As shown in FIGS. 2A and 2B, feeding mice 
human F.IX had a similar effect to the result observed in 
EXAMPLE 1 for OVA, in that it decreased T cell proliferation 
upon subsequent immunization with human F.IX in CFA. 
To demonstrate that oral administration of F.IX induces 
local immunity, hemophiliac B mice were fed transgenic F.IX 
in milk (see EXAMPLE 5) while normal mice did not receive 
F.IX, as described above. Subsequently the level of intestinal 
IgA to FIX was measured by collecting stool samples, dis 
Solving them in PBS, and assaying for IgA using standard 
ELISA methods. As shown in FIG. 2C, feeding F.IX induces 
local immunity as measured by the production of secretory 
IgA. 
EXAMPLE 3 
Antibodies Produced by Orally Tolerized 
Hemophilia B Mice do not Result in Clinical 
Resistance to Infused F.IX 
To measure IgG1 and IgG2a antibodies specific for hF.IX, 
plates were coated with hF.IX (10 ug/ml in PBS) then blocked 
with BSA overnight. After five washes, serum samples from 
the normal and hemophilia B mice fed as described in 
EXAMPLE 2 were added and incubated for two hours. The 
plates were then washed and subsequently incubated with 
HRP-conjugated goat-anti-mouse IgG1 and IgG2a for two 
hours, followed by TMP for color development, and plates 
Subsequently read on an ELISA plate reader. As shown in 
FIGS. 3A and 3B, whereas unfed control mice made strong 
IgG2a antibodies, mice fed with hF.IX made no detectable 
IgG2a, but did produce IgG1. 
Therefore, in normal mice, oral administration of human 
F.IX did not completely inhibit the production of small 
amounts of antibodies after immunization in CFA, as detected 
in ELISA assays, although it caused a shift from IgG2a to 
IgG1 (FIGS. 3A and 3B). However, CFA is the strongest 
adjuvant known, and may elicit antibody production that 
would not occur under conditions that more closely resemble 
a clinical situation. However, antibodies detectable in ELISA 
assays may bind to denatured proteins, but may not act as 
inhibitors of the native protein. Therefore, whether orally 
tolerized hemophiliac mice would make antibodies after CFA 
immunization, and whether these antibodies would act as 
inhibitors and lead to resistance to treatment, was determined. 
Hemophilia B mice were fed transgenic F.IX milk, or fed 
milk without FIX, every other day for two weeks. Two days 
after the last feeding, mice were immunized with h.FIX in 
CFA as described above. Nine days later, the tail vein was 
infused with a dose of F.IXjust over the borderline for cor 
recting the bleeding time (0.13 IU offunctional hF.IX purified 
from the pig milk). This amount was chosen because it is in 
the range of F.IX most sensitive to inhibitors. Bleed times 
were measured six hours later. As shown in FIG. 4, group 2 
shows that this dose of hF.IX partially corrected the bleeding 
time (clotting occurred within 7-10 minutes). This clotting 
time is about twice as long as the 4-6 minutes clotting time of 
normal mice (see FIG. 7A), showing that 0.13 IU of func 
tional hF.IX is a highly sensitive range of factor. Bleeding 
times in the immunized unfed F.IX hemophilia B mice (FIG. 
4, group 3) were as long as those in mice not given factor 
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(FIG. 4, group 1), showing that the antibodies elicited by a 
single immunization with hF.IX in CFA were highly inhibi 
tory. However, the F.IX knock-out mice (hemophilia B mice) 
that were orally tolerized before immunization (FIG. 4, group 
4) showed little evidence of inhibitors, as their bleeding times 
were only slightly longer than those of infused mice that had 
not been immunized. 
These results demonstrate that although orally tolerized 
mice produce antibodies when immunized with a very strong 
adjuvant, these antibodies do not lead to clinical resistance to 
hF.IX infusion. Therefore, the antibodies may be specific for 
denatured forms of the factor that occur in the adjuvant mix 
ture and on ELISA plates, but the antibodies are not inhibitory 
to the native form of hE.IX in vivo. 
EXAMPLE 4 
Casein Oral Tolerance 
This example describes the methods used to determine if 
sheep would develop oral tolerance to casein using the meth 
ods described in EXAMPLES 1 and 2. Similar methods can 
be used to test any antigen of interest, such as F.VIII, F.IX, 
protein C, or insulin, in any animal/subject of interest. 
Lambs were raised on sheep or cow milk. After 3-4 months, 
lambs were immunized with 0.5 mg sheep casein in CFA. 
Three and six weeks later, lambs were boosted with 0.5 mg 
casein in incomplete Freund's adjuvant (IFA) (Sigma). Two 
months after the last immunization, peripheral blood mono 
nuclear cells (PBMCs) were assayed for proliferation in the 
presence of titrated doses of sheep casein. Sheep PBMCs 
were isolated by centrifugating the blood through alymphop 
rep gradient. Cells layered on the lymphoprep were collected 
and cultured in vitro in 96 well plates for four days in the 
presence of casein. Proliferation was measured by pulsing the 
cells with tritiated thymidine during the last eight hours of the 
culture and reading the results on a beta plate counter. 
To measure casein-specific IgG in serum, maleic anhydride 
activated polystyrene plates were coated with sheep casein 
(100 ug/ml) 17 or 30 minutes at 37° C. and blocked with PBS 
1% BSA (bovine serum albumin) for 30 minutes. After dis 
carding the blocking buffer and five washes, serum samples 
(1/10 diluted) were added into the wells and incubated for two 
hours. The plates were Subsequently washed, and horseradish 
peroxidase (HRP) conjugated rabbit anti-sheep IgG (clone 
N126E, Southern Biotechnology Associates) was added and 
incubated for two hours, followed by TMP for color devel 
opment, and plates Subsequently read on all ELISA plate 
reader. 
As shown in FIGS. 5A-5C, oral tolerance occurred in 
sheep. PBMCs from lambs that drank their mother's milk 
(sheep milk) did not proliferate in vitro to a sheep milk pro 
tein, casein, upon immunization as young adults (FIG.5A). In 
contrast, lambs that were fostered on cow's milk showed a 
vigorous proliferative response (FIG. 5B). In addition, orally 
tolerized lambs failed to make antibodies to casein (FIG.5C). 
EXAMPLE 5 
Orally Administered Clotting Factors Remain 
Functional 
Having demonstrated that oral tolerance to several differ 
ent antigens can be achieved, it was then demonstrated that 
the antigen remained functional after passing through the 
digestive system into the bloodstream. This example 
describes methods that were used to test the functionality of 
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F.VIII and F.IX after they were orally administered. Similar 
methods can be used to identify a therapeutically effective 
amount of clotting factor necessary to increase hemostasis in 
a Subject, Such as in a hemophiliac. 
Factor IX 
Normal B10. A mice were fed either 0.5 ml of human F.IX 
in transgenic pig milk (which contained about 2.5 g/l of 
human F.IX; see Van Cottet al. 1999. Genet. Anal. 15:155-60) 
or water alone. One hour after feeding, plasma was obtained 
from the mice and added to sheep T cells that are reactive 
against human F.IX, to determine if the plasma could stimu 
late the sheep PBMCs. Sheep T cells reactive against human 
FIX were generated by immunizing sheep with human F.IX 
(100 g) in CFA. PBMC from these sheep proliferate in a 
dose-dependent manner to purified human F.IX in vitro (FIG. 
4A, dotted line) and therefore can be used to measure the 
amounts of human F.IX in blood samples. The plasma was 
diluted from about 1:10 and decrease in 10-fold dilutions 
down to 1:10. Cells were cultured for four days in 96 well 
plates and pulsed with tritiated thymidine the last eight hours 
of the culture. As a control, sheep T cells were cultured in the 
presence of purified human F.IX. 
As shown in FIG. 6A, F.IX present in the pig milk passed 
into the plasma after feeding. Sheep PBMC responded 
strongly to the fed mouse plasma (FIG. 6A, solid line), but not 
to plasma from unfed mice (FIG. 6A, bottom dashed line). It 
was determined that the fed mouse plasma contained about 
6.7ug/ml of human F.IX, indicating that about 0.1% of the fed 
FIX entered the circulation. This result was confirmed by a 
sandwich ELISA to detect human F.IX in plasma after feed 
ing (FIG. 6B). For the ELISA assay, 96 well flat-bottom 
ELISA plates from PIERCE (Rockford, Ill.) were coated with 
sheep-anti-human F.IX polyclonal antibody (Cedarlane 
Laboratories, Ontario, Canada), then blocked with 10% BSA. 
Mouse plasma were diluted from 1/10 to 1/10,000 and added 
into the wells, incubated for two hours, washed with wash 
buffer, and then HRP-conjugated polyclonal goat anti-human 
F.IX antibodies (Cedarlane Laboratories) added for two 
hours. Color was developed by adding TMP, and results 
obtained using an ELISA plate reader. As shown in FIG. 6B, 
the amount of F.IX in the blood of F.IX-fed mice was similar 
when measured by ELISA to that measured by the PBMC 
(FIG. 6A) and that most F.IX passes into the circulation as 
intact protein. 
To determine if fed human F.IX retains its native form and 
functional ability to treat bleeding episodes, F.IX-containing 
transgenic pig milk (1.25 mg FIX) was fed to hemophilia B 
mice (a F.IX knock-out obtained from Dr. Katherine High, 
Children’s Hospital of Philadelphia; approximately 20 g in 
weight) over a period of two months every other day and the 
effect on a bleeding defect determined. Bleeding time was 
measured by cutting the tip of the tail and waiting for it to clot. 
Normal mice clot in about four minutes (FIG. 7A, open 
squares). In contrast, hemophilia B mice do not stop bleeding 
(FIG. 7A, open circles) and the tail tip is cauterized to stop 
bleeding after fifteen minutes. As shown in FIG. 7A, oral 
administration of F.IX immediately corrected the bleeding 
defect (FIG. 7A, closed circles). In addition, this result is 
sustained for a period of at least two months (FIG. 7B). 
indicating that anti-FIX antibodies are not being generated, 
which allows the F.IX to remain functional. Therefore, oral 
administration of human F.IX is an effective treatment for 
bleeding, and does not induce inhibitory immunity, even fol 
lowing a long-term treatment. 
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Factor VIII 
To demonstrate that hemophilia A, caused by the lack of 
functional F.VIII, could also be treated by oral administration 
of factor, milk from a transgenic pig engineered to secrete 
hF.VIII was fed to F.VIII knock-out mice. However, this 
treatment had no effect on oral tolerance or on clotting times. 
It was possible that the dose of F.VIII was too low, since this 
particular transgenic strain of pig does not produce large 
quantities of F.VIII (Paleyanda et al. Nature Biotech. 15:971 
5, 1997). Another explanation is that hF.VIII is almost 8 times 
larger than F.IX, with a molecular weight of nearly 240,000 
kDa, which might make it difficult to pass into the blood 
Stream. 
To distinguish between these possibilities, the studies were 
repeated with commercially available F.VIII (Baxter) puri 
fied from human plasma (Red Cross Holland labs, Rockville, 
Md.). hF.VIII (100 g) was added to 0.5 ml of water or cow's 
milk and fed to hemophilia A mice by gavage. Bleeding time 
was assayed 45 minutes later. As shown in FIG. 8A, the 
bleeding time was corrected in hemophilia A mice fed hF.VIII 
either in water or milk. Therefore, sufficient hE.VIII passes 
into the bloodstream in native form to function as a clotting 
factor, despite the size and complexity of the molecule. 
To determine whether hE.VIII might be passing through 
Small lacerations created by the gavage process, F.VIII was 
fed to the mice in a more physiologic way, by dissolving 400 
ugh F.VIII in 8 ml of commercial half cream/half milk and 
offering this to the mice in petri dishes. Three mice drank 
about 12 ml of this mixture in about 2 hours, delivering about 
200 ug to each mouse daily. Bleeding time was assayed 45 
minutes later. As shown in FIG. 8B, this method was also an 
effective method to treat the bleeding disorder. 
To demonstrate that feeding hE.VIII induces oral tolerance, 
hF.VIII was fed to hemophilia A mice (F.VIII knock-out 
mice) in commercial half and half (600 ug F.VIII/12 ml of half 
and half) daily foreight days. Control mice were fed plain half 
and half. On day 10, mice were bled to determine the bleeding 
time (FIG. 8C, pre-imm), then immunized with hE.VIII in 
CFA as described in the Examples above. Seven days later, all 
mice were fed hF.VIII-containing half-and-half to determine 
if immunization-induced inhibitors would prevent the oral 
dose of F.VIII from functioning as a clotting factor. 
A single immunization did not inhibit the function of the 
orally administered factor in previously orally tolerized mice 
(FIG. 8C, closed circles), but did cause a loss of function in 
previously unfed controls (FIG. 8C, open circles). The test 
group was fed every other day, starting again from day 19 for 
an additional 7 days. Mice were then boosted with hF.VIII in 
IFA, and again assayed for bleeding time 7 days later. Even 
after this second immunization with a strong adjuvant, the 
previously orally tolerized mice exhibited normal bleeding 
times, while the un-tolerized controls did not. 
The mice were then sacrificed and checked for antibodies 
to F.VIII Control mice had high levels of IgG2a antibodies 
(FIG. 5D, open circles), which is consistent with their inabil 
ity to respond to treatment with hE.VIII. In contrast, the orally 
tolerized mice had barely detectable levels of IgG2a (FIG. 
8D, closed circles). Although orally tolerized mice did have 
some IgG1 antibodies specific for hF.VIII, after immuniza 
tion (FIG. 8C), these antibodies behaved like the similar 
antibodies in orally tolerized wild type mice. These antibod 
ies are not inhibitors, as they did not affect the bleeding time 
(FIG. 8C). 
This is the first demonstration that missing clotting factors 
can be demonstrated in the circulation of hemophiliac mice as 
early as 45 minutes after feeding, and that the orally-fed 
clotting factors are functional, as demonstrated by correction 
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in bleeding time. Although it is commonly assumed that 
dietary proteins are digested completely to free amino acids 
within the lumen of the gastrointestinal tract and that only 
trace amounts of macromolecular fragments enter the circu 
lation having no clinical relevance, there is mounting evi 
dence that Suggests the opposite. The most compelling evi 
dence showing that intact proteins or macromolecular 
fragments are absorbed is provided by the demonstration of 
antibodies to many food proteins that occur in the circulation 
of healthy individuals and experimental animals. For 
example, 5% of recombinant human erythropoietin (about 40 
kDa) fed to 10-day old rats was demonstrated in the serum as 
early as one hour after feeding (Miller-Gilbert et al. 2001. 
Pediatr. Res. 50:261-7). Serum erythropoietin levels 
remained steady for up to 6 hours as opposed to the rapid peak 
and fall observed after intravenous administration. Although 
orally administered erythropoietin showed functional activity 
in Hess mice by stimulation erythropoiesis, this could have 
been due to the stimulation of erythropoietin receptors on the 
enterocytes within the gastrointestinal tract. 
Similarly, gastrointestinal absorption of intact TGFB1 was 
demonstrated after administration (by gavage) of radiola 
beled TGFB into the stomachs of 5-day old pups (Letterio et 
al. 1994. Science 264:1936-8). Although the neonatal gut is 
very permeable to intact proteins, similar results were 
observed in adult animals. In mice, rats, and fish fed ovalbu 
min, casein or HRP respectively, between 0.005 to 0.7% of 
the total fed amount was measured in the circulation either by 
ELISA or Western analysis (Gonnella et al. 2001.J. Immunol. 
1.66:4456-64). Interestingly, the amount of antigen that 
passed into the circulation was much higher in B-cell defi 
cient mice compared to wildtype controls, suggesting that the 
lack of M cells does not affect the transport of proteins across 
the gut. 
Although both intravenous and oral administration of pro 
teins results in detectable serum levels, antigen entry through 
the mucosa provides certain benefits. First, pharmacokineti 
cally, as opposed to a rapid rise and decline as seen after 
intravenous administration, oral administration provides rela 
tively steady levels of the protein. Second, immunologically, 
it generates a gut-oriented immunity, which avoids inhibitory 
or rejecting antibodies. Therefore, feeding F.VIII and FIX in 
hemophilia A and B, respectively, is a simple, noninvasive 
and effective method of treating hemophilia. In addition, it 
induces oral tolerance, avoiding the generation of inhibitory 
antibodies and a vigorous T-cell response against missing 
clotting factors. 
EXAMPLE 6 
Comparison of Oral Administration of Clotting 
Factors in Water and Milk 
To determine if the presence of milk was critical to achieve 
oral tolerance and maintain proper function of the clotting 
factor, the administration of F.VIII or F.IX in milk and water 
was compared. 
Purified F.VIII from human serum was orally administered 
to hemophilia A mice (F.VIII knock out; Dr. Kanig, U. of 
Iowa.) in cow's milk or in water. Mice were fed 100 ug of 
F.VIII (antihemophilic factor, Baxter, Deerfield, Ill.) by gav 
age in 1.5 ml of water or cow's milk. Bleeding time was 
measured as described above, 45 minutes after feeding. As 
shown in FIG. 8A, feeding F.VIII derived from human plasma 
that is added into cow's milk or water corrects bleeding time 
in hemophilia A mice. Therefore, the presence of milk when 
orally administering F.VIII is not critical. 
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To determine if the presence of milk was critical to achieve 
oral tolerance to FIX, normal B10. A mice were fed with low 
(10-20 ug F.IX/feed) or high (2500 ug F.IX/feed) does of 
human F.IX in pig milk or as purified plasma-derived human 
F.IX (Sigma) reconstituted in water (10-20 ug F.IX/feed) 
every other day for a total offive feeds. Control mice were fed 
no F.IX. Two days later, mice were immunized with 0.5 lug 
human F.IX emulsified in CFA at the base of the tail. Seven 
days later, the amount of T cell proliferation was determined 
using the methods described in EXAMPLE 1. As shown in 
FIGS.9A and 9B, mice fed as little as 20 ug F.IX in milk (FIG. 
9A) were almost completely unresponsive, while T cells from 
mice fed with F.IX in water (FIG.9B) retained a small amount 
of activity (about 3% of unfed controls). However, adminis 
tration of F.IXinwater or milk resulted in better oral tolerance 
than no administration of F.IX. 
In summary, a dose of 100 ug F.VIII/20 g body weight 
(about 5 mg/kg), orally administered every day (or every 
other day), can be used to increase hemostasis, thus treating 
hemophilia A. In addition, a dose of 1 mg FIX/20 g body 
weight (about 50 mg/kg), orally administered every day (or 
every other day), is expected to increase hemostasis thus 
treating hemophilia B. However, it is possible that lower 
doses can be used, or that higher doses may be required in a 
particular Subject, in order to obtain a successful treatment of 
hemophilia. 
EXAMPLE 7 
Determination of Parameters for Low Dose Oral 
Tolerance 
To identify optimal conditions to achieve low dose oral 
tolerance to human F.IX delivered in transgenic pig milk, the 
following methods can be used. Similar methods can be used 
to determine the conditions for other antigens, including 
F.VIII, insulin, and protein C, in humans. 
Lambs can be used as an experimental model. Sheep are an 
outbred species and, like humans (but unlike mice), their 
immune system becomes functional during the last trimester 
of pregnancy. They are also easier than mice to bottle-feed. 
The architecture of sheep intestines during the first 24-48 
hours of life is designed to collect maternal antibodies from 
colostrum, with very high levels of Fc receptors that have a 
half-life of about 24 hours. Therefore, feeding of F.IX milk is 
started 48 hours after birth, when the gut has settled. 
Lambs are fed 0.3 mg F.IX/kg of animal/day, the amount of 
protein shown to induce low dose tolerance in 20 g mice 
(FIGS. 1A-1C). The effective dose range in mice is 0.001 to 
0.1 mg for OVA (0.05-5 mg/kg) and 0.003 to 0.1 mg/day for 
F.IX (0.15-0.5 mg/kg). Lambs are fed daily for three weeks 
with sheep milk Supplemented with pig milk containing 
human F.IX (see EXAMPLE 5). A parallel control group of 
lambs is Supplemented with normal pig milk containing no 
human F.IX. Milk is collected, frozen immediately, and 
thawed just before use. Experiments with mice demonstrate 
that continuous daily feeding is the most effective way of 
inducing oral tolerance. 
Sheep can be immunized as early as two weeks of age. At 
three weeks of age, half the lambs are immunized with F.IX in 
CFA after the feedings are completed and then boosted two 
weeks later with F.IX in IFA. A dose of 100 ug human F.IX is 
Sufficient to prime young ewes for a Subsequent proliferative 
and antibody response. Lambs are tested for various types of 
immunity against F.IX after each immunization. 
Three assays can he used to detect immune responses 
against F.IX. First, the amount of peripheral blood mono 
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nuclear cell proliferation can be determined. One week and 
two weeks after immunization, 10-20 ml of venous blood is 
collected by jugular Venipuncture, the mononuclear cells 
fractionated using Percoll gradients and Subsequently cul 
tured in vitro in the presence of titrated amounts of F.IX, and 
assay for proliferation as described in EXAMPLES 1, 2 and 4. 
Second, serum F.IX specific antibody titers can be deter 
mined. From each blood sample collected, serum is extracted. 
Dilutions of the serum are added to ELISA plates (Pierce) 
coated with human F.IX (101 g/ml). After a two hour incuba 
tion, the plates are washed with wash buffer, then incubated 
with polyclonal HRP-conjugated goat anti-human F.IX anti 
bodies (Cedarlane Laboratories) for two hours. For color 
development TMP is added and then the plates are read in an 
ELISA plate reader. Antibodies of different classes can be 
identified using the sandwich ELISA method described in 
EXAMPLES 4 and 5. 
Third, a factor IX inhibitor assay (Bethesda Assay) can be 
conducted. This functional assay measures the amount of 
inhibitor antibody in serum. The Bethesda assay is an in vitro 
functional assay performed by mixing plasma containing 
unknown amounts of inhibitors (test plasma) with normal 
plasma to determine how the test plasma prolongs the APTT 
of the normal plasma. 
Lambs fed human F.IX should not generate a strong spe 
cific proliferative response, and should not develop antibod 
ies against FIX. If antibodies are produced, they will be of the 
secretory IgA type and will not be inhibitory against F.IX. 
It is possible that the determined effective dose in sheep or 
other Subjects (such as humans) may differ from that in mice. 
If feeding 0.3 mg/kg/day F.IX does not result in oral toler 
ance, experiments can be repeated using a titration of higher 
and lower doses of F.IX, to determine the appropriate dose. In 
addition, it can also be determined whether feeding during the 
first 48 hours of life can enhance oral tolerance. 
EXAMPLE 8 
Determination of Parameters for High Dose Oral 
Tolerance 
To determine parameters that are helpful to achieve opti 
mal high dose oral tolerance to human F.IX delivered in 
transgenic pig milk, the following methods can be used. Simi 
lar methods can be used to determine the parameters for other 
antigens, including F.VIII, insulin, and protein C. 
Although low dose tolerance induces remarkable reduc 
tions in cellular responses, it may allow for some antibody 
production. Though antibodies are unlikely to result in rejec 
tion of cells expressing a FIX transgene, they may inhibit the 
secreted product. Therefore, tolerance can also be induced by 
feeding high doses of F.IX. This approach has not been fea 
sible in the past because of the extraordinarily high cost of 
purified F.IX. However, induction of oral tolerance does not 
require purified antigen. As experiments in sheep illustrate 
(FIGS. 5A-5C), newborns become tolerant of milk proteins 
even when the proteins are given as mixtures in normal milk. 
The tolerizing ability of unpurified transgenic pig milk con 
taining 2.5 g/L F.IX (see EXAMPLE5) in the native situation 
where piglets feed continuously is tested. 
Non-transgenic piglets are fostered onto transgenic moth 
ers and allowed to drink ad libitum until weaned. A control 
group of foster littermates is fostered onto non-transgenic 
control mothers. Two days after the animals are weaned, half 
of the piglets in each group are Subcutaneously immunized 
with F.IX (0.1 mg) in CFA and two weeks later, boosted with 
F.IX in IFA. Half of the piglets will be un-immunized as 
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controls. One and two weeks after each immunization various 
classes of immunity will be determined as described above in 
EXAMPLE 7. 
Piglets that drank F.IX containing milk from transgenic 
mothers are expected to be tolerant to FIX. This tolerance is 
tested by Subsequently immunizing these piglets to human 
F.IX in CFA as described in the examples above. Tolerance is 
achieved if there is decreased antibody formation and T cell 
proliferation in these piglets compared to piglets fostered 
onto a non-transgenic mother using the methods described in 
the examples above. 
EXAMPLE 9 
Oral Tolerance in Hemophiliac Puppies 
This example describes procedures that can be used to 
develop oral tolerance to clotting factors in hemophiliac pup 
pies. The method specifically outlines methods for testing 
tolerance to FIX in hemophiliac B puppies, but those skilled 
in the art will understand from the teachings herein that simi 
lar methods can be used to test for tolerance to F.VIII in 
hemophiliac A puppies, or for tolerance to any antigen in any 
Subject having an antigen-deficiency disease. 
A canine model of hemophilia A is available (Giles et al. 
1982. Blood 60:727-30; and Giles et al. 1984. Blood 63:451 
6). Hemophilia A was diagnosed in a miniature Schnauzer 
dog and inbreeding and crossbreeding produced 16 hemo 
philic animals. Five animals developed potent antibodies to 
canine F.VIII. In each case, the antibodies recognize both 
canine and human, but not porcine F.VII. Following inhibitor 
development, infusion of canine cryoprecipitate was hemo 
statically ineffective and F.VIII recovery at 30 minutes is 
negligible. 
Two canine models of hemophilia B are available. In the 
Chapel Hill dog colony, hemophilia B is due to a missense 
mutation, and inhibitor formation in response to canine 
plasma or gene therapy maneuvers is relatively uncommon 
(Evans et al. 1989. Proc. Natl. Acad. Sci. USA. 86:10095-9). 
However, for the Auburn dog colony, where disease is due to 
a small deletion that results in an early stop codon (Mauser et 
al. 1996. Blood. 88:3451-5), inhibitor formation is more fre 
quent. In both types of mutations, inhibitors to canine F.IX 
can be induced by various means including repeated injection 
of purified canine F.IX, or injection of vector expressing 
canine F.IX. The rise in inhibitor antibodies correlates with 
fall of plasma F.IX levels (Herzog et al. 1999. Nat. Med. 
5:56–63). Both colonies of dogs readily form inhibitory anti 
bodies following infusion of human F.IX. 
To assess the effect of oral tolerance on the development of 
clotting factor inhibitors after immunization, canine models 
for hemophilia are used, F.IX is administered orally to normal 
puppies and to puppies with hemophilia B (Auburn dog 
colony) and their spontaneous immune responses against 
F.IX analyzed. 
The optimal feeding dose of F.IX found to prevent devel 
opment of inhibitory antibodies is used (see EXAMPLES 
5-8). Normal and hemophilia B puppies are divided into two 
groups: one group is fed FIX-containing transgenic pig milk, 
and the other group fed non-transgenic pig milk to serve as 
controls. Puppies are fed for six weeks until they are fully 
weaned. 
The puppies are then infused with 50 IU/kg human F.IX 
intravenously daily for two weeks, starting two days after 
weaning, or earlier if necessary to control bleeding. The gen 
eration of inhibitor antibodies after repeated intravenous 
administration of human F.IX has been well established in the 
5 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
24 
canine model (Evans et al. 1989. Proc. Natl. Acad. Sci. USA. 
86:10095-9). The course of the disease is followed, periodi 
cally assaying for inhibitory antibodies using the Bethesda 
assay (see EXAMPLE 7), especially after F.IX infusions due 
to bleeding episodes. 
PBMC proliferation and serum antibody titers against FIX 
are also compared between control and experimental animals, 
as described in EXAMPLE 4, except that the in vitro assays 
are modified to suit canine cells. For example, IMDM plus 
canine serum is a Superior medium for canine proliferation 
assays whereas RPMI plus fetal calf serum serves well for 
sheep. 
It is expected that the intact antigen will gain access to the 
bloodstream after feeding, as was obtained for F.IX in mice 
(EXAMPLE 5). To test for F.IX in plasma samples from 
F.IX-fed hemophilia B and normal puppies, methods 
described in EXAMPLE 5 are used. 
To determine if the F.IX antigen remains functional after 
oral administration, a functional assay is performed. For 
example, an APTT assay which measures the intrinsic coagu 
lation activity of the plasma can be used. 
Therefore, in addition to orally tolerizing the immune sys 
tem, it is determined whether small amounts of functional 
F.IX can reach the blood and help prevent bleeding episodes, 
thus increasing hemostasis. 
It is expected that oral administration of F.IX by feeding 
will induce oral tolerance and prevent the development of 
inhibitory antibodies, as well as remain functional in the 
blood, and therefore increase hemostasis and serve as a treat 
ment for hemophilia. 
EXAMPLE 10 
Oral Administration Followed by in Vivo Gene 
Expression 
To demonstrate that administration and Subsequent expres 
sion of a FIX-containing transgene can be used to treat hemo 
philia, adeno-associated vectors containing a FIX gene can 
be used. 
After orally tolerizing puppies to FIX as described in 
EXAMPLE 9, adeno-associated viral vectors are used to 
introduce the human F.IX gene into hemophiliac puppies 
orally tolerized to human F.IX to increase hemostasis. Similar 
methods can be used in human hemophiliacs. 
Methods for generating an introducing transgenes into a 
subject are well known in the art. In addition, viral vectors for 
introducing a clotting factor into a subject are known. 
Examples of methods and vectors that can be used to intro 
duce a clotting factor into a Subject, include, but are not 
limited to those disclosed in: Stein et al., 2001. Mol. Ther. 
3:850-6: Miller et al., 2001. N. Engl. J. Med. 344:1782-4: 
Emilien et al., 2000. Clin. Lab. Haematol. 22:313-23: 
Andrews et al., 2001. Mol. Ther: 3:329-36; Fabb et al., 2000. 
Curr. Opin. Mol. Ther. 2:601-6; and Lillicrap, 2000. Haema 
tologica 85(10 Suppl): 108-12, as well as other documents 
cited herein. 
Following administration of the vector, F.IX levels in 
serum, as well as immunity to FIX, are monitored as 
described in EXAMPLES 5 and 7, over a period of one year 
or until the factor disappears, whichever comes first. 
It is expected that oral administration of a clotting factor by 
feeding will induce oral tolerance and prevent the develop 
ment of inhibitory antibodies, such that when the factor is 
Subsequently expressed recombinantly in the Subject, the 
recombinant protein will not be inactivated by anti-clotting 
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factor antibodies. This will result in functional clotting factor 
in the blood, and therefore increase hemostasis and serve as a 
treatment for hemophilia. 
EXAMPLE 11 
Oral Tolerance and Treatment in Humans 
This example describes methods that can be used to induce 
tolerance to F.IX in a human hemophiliac. Similar methods 
can be used to induce oral tolerance to any antigen of interest 
in a human subject, for example F.VIII, insulin and protein C. 
Among hemophilia patients that form inhibitors, the inci 
dence of patients with large deletions is known (deletion/total 
inhibitor production=0.5). However, due to the cost of wide 
spread genetic screening, and the lack of practical conse 
quence to the management of hemophilia patients, the inci 
dence of inhibitorproducers among those with large deletions 
is not known (inhibitor production/large deletions). 
The patient group most likely to benefit from treatment are 
children that have no F.IX, thus making them particularly 
prone to making inhibitors. After determining the F.IX levels 
in plasma of a hemophiliac child, patients having undetect 
able levels are further tested to determine whether they have 
a large F.IX deletion. From this study, the incidence of inhibi 
tor producers among those who have large deletions can be 
determined. 
From studies on hemophiliac puppies, patients with large 
deletions are believed to be particularly prone to making 
inhibitors and thus particularly at risk of becoming refractory 
to replacement therapy. 
Hemophiliac children are orally tolerized by oral adminis 
tration (feeding) of F.IX-containing transgenic milk. Alterna 
tively, purified FIX can be administered orally in any medium 
Suitable for oral administration, including water. 
The immune response to F.IX during the course of the 
disease is monitored as described in EXAMPLE 7. In addi 
tion, the amount of functional F.IX in the blood, the formation 
of antibodies against F.IX and PBMC proliferation are moni 
tored as described above. 
In addition, hemostasis is monitored, using an APTT assay 
described in EXAMPLE 7 or a bleeding time assay. Treat 
ment is successful if hemostasis is increased relative to hemo 
Stasis prior to oral administration of the clotting factor, or 
relative to untreated hemophiliacs. 
EXAMPLE 12 
Oral Tolerance Followed by in Vivo Gene 
Expression 
As an alternative to continually orally administering a clot 
ting factor to a subject to increase hemostasis, once oral 
tolerance is achieved, long term treatment of the clotting 
disorder can be achieved by expressing the deficient clotting 
factor in vivo. Similar methods can be used to treat any 
antigen-deficiency disease. 
The present disclosure provides methods of expressing a 
protein in a cell or tissue in vivo. In one embodiment, trans 
fection of the cellor tissue occurs in vitro. In this example, the 
cell or tissue (Such as a graft) is removed from a subject and 
then transfected with an expression vector containing a 
cDNA encoding the protein of interest. The transfected cells 
will produce functional protein and can be reintroduced into 
the Subject. In another embodiment, a nucleic acid encoding 
the protein of interest is administered to a subject directly, and 
transfection occurs in vivo. 
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The methods disclosed herein can be used to treating a 
Subject with an antigen-deficiency disease such as a subject 
having hemophilia A or B. Such a method would increase 
hemostasis (decrease blood clotting time) in, hemophiliacs or 
Subjects having other defects in blood clotting. 
The scientific and medical procedures required for human 
cell transfection are now routine. The public availability of 
numerous protein and cDNA sequences allows the develop 
ment of human (and other mammals) in vivo gene expression 
based upon these procedures. Immunotherapy of melanoma 
patients using genetically engineered tumor-infiltrating lym 
phocytes (TILs) has been reported by Rosenberg et al. (N. 
Engl. J. Med. 323:570-8, 1990). In that study, a retrovirus 
vector was used to introduce a gene for neomycin resistance 
into TILS. A similar approach may be used to introduce a 
clotting factor cDNA into hemophiliacs. 
In some embodiments, a method of treating Subjects which 
under express a functional protein, or in which greater func 
tional protein expression is desired, is disclosed. These meth 
ods can be accomplished by introducing a gene coding for the 
desired protein into a Subject. A general strategy for transfer 
ring genes into donor cells is disclosed in U.S. Pat. No. 
5,529.774, incorporated by reference. Generally, a gene 
encoding a protein having therapeutically desired effects is 
cloned into a viral expression vector, and that vector is then 
introduced into the target organism. The virus infects the 
cells, and produces the protein sequence in Vivo, where it has 
its desired therapeutic effect. Zabner et al. (Cell 75:207-16, 
1993). 
It may only be necessary to introduce the genetic or protein 
elements into certain cells or tissues. However, in some 
instances, it may be more therapeutically effective and simple 
to treat all of a subject’s cells, or more broadly disseminate the 
vector, for example by intravascular (i.v.) administration. 
The nucleic acid sequence encoding at least one therapeu 
tic agent, such as a clotting factor, is under the control of a 
suitable promoter. Suitable promoters which may be 
employed include, but are not limited to, the gene's native 
promoter, retroviral LTR promoter, or adenoviral promoters, 
such as the adenoviral major late promoter; the CMV pro 
moter; the RSV promoter; inducible promoters, such as the 
MMTV promoter; the metallothionein promoter; heat shock 
promoters; the albumin promoter; the histone promoter; the 
C.-actin promoter, TK promoters: B19 parvovirus promoters: 
and the ApoAI promoter. However the scope of the disclosure 
is not limited to specific foreign genes or promoters. 
The recombinant nucleic acid can be administered to the 
subject by any method which allows the recombinant nucleic 
acid to reach the appropriate cells. These methods include 
injection, infusion, deposition, implantation, or topical 
administration. Injections can be intradermal or Subcutane 
ous. The recombinant nucleic acid can be delivered as part of 
a viral vector, Such as avipox viruses, recombinant vaccinia 
virus, replication-deficient adenovirus strains or poliovirus, 
or as a non-infectious form Such as naked DNA or liposome 
encapsulated DNA, as further described in EXAMPLE 13. 
EXAMPLE 13 
Viral Vectors for in Vivo Gene Expression 
Adenoviral vectors include essentially the complete aden 
oviral genome (Shenk et al., Curr: Top. Microbiol. Immunol. 
1 11:1-39, 1984). Alternatively, the adenoviral vector is a 
modified adenoviral vector in which at least a portion of the 
adenoviral genome has been deleted. In one embodiment, the 
vector includes an adenoviral 5"ITR; an adenoviral 3'ITR; an 
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adenoviral encapsidation signal; a DNA sequence encoding a 
therapeutic agent, and a promoter for expressing the DNA 
sequence encoding atherapeutic agent. The vectoris free of at 
least the majority of adenoviral E1 and E3 DNA sequences, 
but is not necessarily free of all of the E2 and E4 DNA 5 
sequences, and DNA sequences encoding adenoviral proteins 
transcribed by the adenoviral major late promoter. In another 
embodiment, the vector is an adeno-associated virus (AAV) 
such as described in U.S. Pat. No. 4,797,368 (Carteret al.)and 
in McLaughlin et al. (J. Virol. 62:1963-73, 1988) and AAV 10 
type 4 ((Chiorini et al. J. Virol. 71:6823-33, 1997) and AAV 
type 5 (Chiorini et al. J. Virol. 73:1309-19, 1999). 
Such a vector can be constructed according to standard 
techniques, using a shuttle plasmid which contains, begin 
ning at the 5' end, an adenoviral 5'ITR, an adenoviral encapsi- 15 
dation signal, and an E1a enhancer sequence; a promoter 
(which may be an adenoviral promoter or a foreign pro 
moter); a tripartite leader sequence, a multiple cloning site 
(which may be as herein described); a poly A signal; and a 
DNA segment which corresponds to a segment of the aden- 20 
oviral genome. The DNA segment serves as a substrate for 
homologous recombination with a modified or mutated aden 
ovirus, and may encompass, for example, a segment of the 
adenovirus 5' genome no longer than from base 3329 to base 
6246. The plasmid can also include a selectable marker and an 25 
origin of replication. The origin of replication may be a bac 
terial origin of replication. A desired DNA sequence encod 
ing a therapeutic agent can be inserted into the multiple clon 
ing site of the plasmid. 
Examples of vectors which can be used to practice the 30 
methods disclosed herein include those disclosed in: WO 
95/27512 to Woo et al., WO 127303 to Walsh et al.: U.S. Pat. 
No. 6,221.349 to Couto et al.; U.S. Pat. No. 6,093,392 to High 
et al. 
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EXAMPLE 1.4 
Production of Sequence Variants 
Disclosed herein methods for treating antigen-deficiency 40 
diseases by oral administration of the appropriate antigen or 
protein. It is understood by those skilled in the art that use of 
non-native antigen sequences (such as polymorphisms, frag 
ments, or variants) can be used to practice the methods of the 
present disclosure, as long as the distinctive functional char- 45 
acteristics of the antigen are retained. For example, F.IX or 
F.VIII variants can be used to practice the methods disclosed 
herein if they retain their ability to increase hemostasis. This 
activity can readily be determined using the assays disclosed 
herein, for example those described in EXAMPLES 5 and 9. So 
In yet other embodiments, F.IX or F.VIII has the distinct 
characteristic of being reduced in patients suffering from 
hemophilia. 
This disclosure facilitates the use of DNA molecules, and 
thereby proteins, derived from a native protein but which vary 55 
in their precise nucleotide or amino acid sequence from the 
native sequence. Such variants can be obtained through stan 
dard molecular biology laboratory techniques and the 
sequence information disclosed herein. 
DNA molecules and nucleotide sequences derived from a 60 
native DNA molecule can also be defined as DNA sequences 
which hybridize under stringent conditions to the DNA 
sequences disclosed, or fragments thereof. Hybridization 
conditions resulting in particular degrees of stringency vary 
depending upon the nature of the hybridization method and 65 
the composition and length of the hybridizing DNA used. 
Generally, the temperature of hybridization and the ionic 
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strength (especially the Na" concentration) of the hybridiza 
tion buffer determines hybridization stringency. Calculations 
regarding hybridization conditions required for attaining par 
ticular amounts of stringency are discussed by Sambrook et 
al. (Molecular Cloning: A Laboratory Manual, Cold Spring 
Harbor, N.Y., 1989, Chapters 9 and 11), herein incorporated 
by reference. Hybridization with a target probe labeled with 
'P-dCTP is generally carried out in a solution of high ionic 
strength such as 6xSSC at a temperature that is about 5-25°C. 
below the melting temperature, T. An example of stringent 
conditions is a salt concentration of at least about 0.01 to 1.0 
MNaion concentration (or other salts) at pH 7.0 to 8.3 and a 
temperature of at least about 30°C. for short probes (e.g. 10 
to 50 nucleotides). Stringent conditions can also be achieved 
with the addition of destabilizing agents such as formamide. 
For example, conditions of 5xSSPE (750 mM. NaCl, 50 mM 
Naphosphate, 5 mM EDTA, pH 7.4) at 25-30°C. are suitable 
for allele-specific probe hybridizations. 
The degeneracy of the genetic code further widens the 
Scope of the present disclosure as it enables major variations 
in the nucleotide sequence of a DNA molecule while main 
taining the amino acid sequence of the encoded protein. For 
example, the amino acid Ala is encoded by the nucleotide 
codon triplet GCT, GCG, GCC and GCA. Thus, the nucle 
otide sequence could be changed without affecting the amino 
acid composition of the encoded protein or the characteristics 
of the protein. Based upon the degeneracy of the genetic code, 
variant DNA molecules may be derived from a cDNA mol 
ecule using standard DNA mutagenesis techniques as 
described above, or by synthesis of DNA sequences. DNA 
sequences which do not hybridize under stringent conditions 
to the cDNA sequences disclosed by virtue of sequence varia 
tion based on the degeneracy of the genetic code are also 
comprehended by this disclosure. 
Clotting factor variants, fragments, fusions, and polymor 
phisms will retain the ability to increase hemostasis, as deter 
mined using the assays disclosed herein, for example by 
performing an APTT assay (EXAMPLE 9) or a bleeding time 
assay. Variants and fragments of a protein may retain at least 
70%, 80%, 85%, 90%, 95%, 98%, or greater sequence iden 
tity to a protein amino acid sequence and maintain the func 
tional activity of the protein as understood by those in skilled 
in the art. Examples of clotting factor variants, include, but 
are not limited to those disclosed in U.S. Pat. No. 6,221.349 to 
Couto et al.; U.S. Pat. No. 4,877,614 to Andersson et al.; EP 
770396 to Zimmermann et al.; U.S. Pat. No. 6,093,392 to 
High et al.; and EP 0294.910 to van Ooyen et al. 
EXAMPLE 1.5 
Recombinant Expression of Proteins 
With publicly available cDNA and corresponding amino 
acid sequences, as well as the disclosure herein of variants, 
fragments and fusions thereof, the expression and purification 
of any publicly known protein by standard laboratory tech 
niques is enabled. The purified protein can be used for patient 
therapy. For example, mammals that produce recombinant 
F.VIII or F.IX in their milk are known (see U.S. Pat. No. 
5,880,327 to Lubon et al. and Van Cott et al. 1999. Genet. 
Anal. 15:155-60, respectively), and can be used to practice the 
methods disclosed herein. However, one skilled in the art will 
understand that the orally administered clotting factor can be 
produced in any cellor organism of interest, and purified prior 
to administration to a Subject, as an alternative to feeding the 
Subject milk containing the recombinant clotting factor. 
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Methods for producing recombinant proteins are well 
known in the art. Therefore, the scope of this disclosure 
includes recombinant expression of any antigen/protein. For 
example, see U.S. Pat. No. 5,342,764 to Johnson et al.; U.S. 
Pat. No. 5,846,819 to Pausch et al.; U.S. Pat. No. 5,876,969 to 
Fleer et al. and Sambrook et al. (Molecular Cloning: A Labo 
ratory Manual, Cold Spring Harbor, N.Y., 1989, Ch. 17, 
herein incorporated by reference). 
In addition, methods for producing recombinant clotting 
factors are known, for example as disclosed in EP 0294910 
(and references therein); EP 0160457; EP 0253.455; EP 
O150735; U.S. Pat. No. 6,221,349 to Couto et al.; U.S. Pat. 
No. 5,804,420 to Chan et al. and U.S. Pat. No. 4,770,999 to 
Kaufman et al. 
EXAMPLE 16 
Peptide Modifications 
Orally administered proteins can be modified using a vari 
ety of chemical techniques to produce derivatives having 
essentially the same activity as the unmodified peptides, and 
optionally having other desirable properties. For example, 
carboxylic acid groups of the peptide, whether carboxyl 
terminal or side chain, can be provided in the form of a salt of 
a pharmaceutically-acceptable cation or esterified to form a 
C-C ester, or converted to an amide of formula NRR 
wherein RandR are each independently H or C-C alkyl, 
or combined to form a heterocyclic ring, Such as a 5- or 
6-membered ring. Amino groups of the peptide, whether 
amino terminal or side chain, can be in the form of a pharma 
ceutically-acceptable acid addition salt, such as the HCl, HBr, 
acetic, benzoic, toluene Sulfonic, maleic, tartaric and other 
organic salts, or may be modified to C-C alkyl or dialkyl 
amino or further converted to all amide. 
Hydroxyl groups of the peptide side chain can be converted 
to C-C alkoxy or to a C-C ester using well-recognized 
techniques. Phenyl and phenolic rings of the peptide side 
chain can be substituted with one or more halogen atoms, 
Such as F, Cl, Br or I, or with C-C alkyl, C-C alkoxy, 
carboxylic acids and esters thereof, or amides of Such car 
boxylic acids. Methylene groups of the peptide side chains 
can be extended to homologous C-C alkylenes. Thiols can 
be protected with any one of a number of well-recognized 
protecting groups, such as acetamide groups. Those skilled in 
the art will also recognize methods for introducing cyclic 
structures into the peptides disclosed herein to select and 
provide conformational constraints to the structure that result 
in enhanced Stability. For example, a carboxyl-terminal or 
amino-terminal cysteine residue can be added to the peptide, 
so that when oxidized the peptide will contain a disulfide 
bond, generating a cyclic peptide. Other peptide cyclizing 
methods include the formation of thioethers and carboxyl 
and amino-terminal amides and esters. 
To maintain a functional peptide, particular peptide vari 
ants will differ by only a small number of amino acids from a 
peptide. Such variants can have deletions (for example of 1-3 
or more amino acids), insertions (for example of 1-3 or more 
residues), or substitutions that do not interfere with the 
desired activity of the peptide. Substitutional variants are 
those in which at least one residue in the amino acid sequence 
has been removed and a different residue inserted in its place. 
In particular embodiments, such variants have amino acid 
substitutions of single residues, for example 1, 3, 5 or even 10 
Substitutions in a protein. 
Peptidomimetic and organomimetic embodiments are also 
disclosed herein, whereby the three-dimensional arrange 
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ment of the chemical constituents of such peptido- and orga 
nomimetics mimic the three-dimensional arrangement of the 
peptide backbone and component amino acid sidechains in 
the peptide, resulting in Such peptido- and organomimetics of 
a clotting factor having the ability to increase hemostasis. For 
computer modeling applications, a pharmacophore is an ide 
alized, three-dimensional definition of the structural require 
ments for biological activity. Peptido- and organomimetics 
can be designed to fit each pharmacophore with current com 
puter modeling software (using computer assisted drug 
design or CADD). See Walters, “Computer-Assisted Model 
ing of Drugs’, in Klegerman & Groves, eds., 1993, Pharma 
ceutical Biotechnology, Interpharm Press: Buffalo Grove, 
Ill., pp. 165-174 and Principles of Pharmacology (ed. Mun 
son, 1995), chapter 102 for a description of techniques used in 
CADD. 
EXAMPLE 17 
Pharmaceutical Compositions and Modes of 
Administration 
The pharmaceutically effective carriers useful herein are 
conventional. Remington's Pharmaceutical Sciences, by 
Martin, Mack Publishing Co., Easton, Pa., 15th Edition 
(1975), describes compositions and formulations suitable for 
pharmaceutical delivery. 
Oral Administration of Antigens and Proteins 
In an embodiment in which an antigen, such as a clotting 
factor, is administered to a subject, the antigen is delivered 
enterally, for example orally (e.g., by feeding), or rectally 
(e.g., by Suppository). The present disclosure also provides 
pharmaceutical compositions which includeatherapeutically 
effective amount of a clotting factor alone or with a pharma 
ceutically acceptable carrier. Furthermore, the pharmaceuti 
cal compositions or methods of treatment can be adminis 
tered in combination (or separately) with one or more other 
therapeutic treatments. Such as other agents that increase 
hemotasis. Embodiments of the disclosure comprising medi 
caments can be prepared with conventional pharmaceutically 
acceptable carriers, adjuvants and counterions as would be 
known to those of skill in the art. 
The antigen can be administered in combination with at 
least one, for example one or more pharmaceutically effective 
carriers, such as a pharmaceutically and physiologically 
acceptable fluid. Examples of pharmaceutically effective car 
riers include, but are not limited to milk, water, physiological 
saline, balanced salt solutions, aqueous dextrose, sesame oil, 
glycerol, ethanol, combinations thereof, or the like, as a 
vehicle. The carrier and composition can be sterile, and the 
formulation Suits the mode of administration. In addition to 
biologically-neutral carriers, pharmaceutical compositions to 
be administered can contain minor amounts of non-toxic 
auxiliary Substances, such as wetting or emulsifying agents, 
preservatives, and pH buffering agents and the like, for 
example sodium acetate or Sorbitan monolaurate. 
The composition can be a liquid solution, Suspension, 
emulsion, tablet, pill, capsule, Sustained release formulation, 
or powder, but not a liposome also containing a protease 
inhibitor. For Solid compositions (e.g., powder, pill, tablet, or 
capsule forms), conventional non-toxic solid carriers can 
include, for example, pharmaceutical grades of mannitol, 
lactose, starch, Sodium saccharine, cellulose, magnesium car 
bonate, or magnesium Stearate. The composition can be for 
mulated as a Suppository, with traditional binders and carriers 
Such as triglycerides. 
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The amount of antigen, such as a clotting factor, effective in 
the treatment of a particular disorder or condition, Such as 
hemophilia, will depend on the nature of the disorder or 
condition, and can be determined by standard clinical tech 
niques. In addition, in vitro assays can be employed to iden 
tify optimal dosage ranges (see EXAMPLES 7 and 8). The 
precise dose to be employed in the formulation will also 
depend on the seriousness of the disease or disorder, and 
should be decided according to the judgment of the practitio 
ner and each subjects circumstances. Effective doses can be 
extrapolated from dose-response curves derived from in vitro 
or animal model test systems. 
The disclosure also provides a pharmaceutical pack or kit 
comprising one or more containers filled with one or more of 
the ingredients of the pharmaceutical compositions. Option 
ally associated with Such container(s) can be a notice in the 
form prescribed by a governmental agency regulating the 
manufacture, use or sale of pharmaceuticals or biological 
products, which notice reflects approval by the agency of 
manufacture, use or sale for human administration. Instruc 
tions for use of the composition can also be included. 
Administration of Nucleic Acid Molecules 
In an embodiment in which a nucleic acid is employed to 
allow expression of a nucleic acid in a cell, the nucleic acid is 
delivered intracellularly (e.g., by expression from a nucleic 
acid vector or by receptor-mediated mechanisms). In one 
embodiment, a nucleic acid encodes for an antigen, such as a 
clotting factor. 
Various delivery systems for administering a nucleic acid 
are known, and include encapsulation in liposomes, micro 
particles, microcapsules, receptor-mediated endocytosis (Wu 
and Wu, J. Biol. Chem. 1987,262:4429-32), and construction 
of therapeutic nucleic acids as part of a retroviral or other 
vector. Methods of introduction include, but are not limited 
to, intradermal, intramuscular, intraperitoneal, intravenous, 
Subcutaneous, intranasal, and oral routes. The compounds 
may be administered by any convenient route, for example by 
infusion or bolus injection, by absorption through epithelial 
or mucocutaneous linings (e.g., oral mucosa, rectal, Vaginal 
and intestinal mucosa, etc.) and may be administered together 
with other biologically active agents. Administration can be 
systemic or local. Pharmaceutical compositions can be intro 
duced into the central nervous system by any Suitable route, 
including intraventricular and intrathecal injection; intraven 
tricular injection may be facilitated by an intraventricular 
catheter, for example, attached to a reservoir. Such as an 
Ommaya reservoir. 
Liposomes fuse with the target site and deliver the contents 
of the lumen intracellularly. The liposomes are maintained in 
contact with the target cells for a sufficient time for fusion to 
occur, using various means to maintain contact, Such as iso 
lation and binding agents. Liposomes can be prepared with 
purified proteins or peptides that mediate fusion of mem 
branes. Such as Sendai virus or influenza virus. The lipids may 
be any useful combination of known liposome forming lipids, 
including cationic lipids, such as phosphatidylcholine. Other 
potential lipids include neutral lipids, such as cholesterol, 
phosphatidyl serine, phosphatidylglycerol, and the like. For 
preparing the liposomes, the procedure described by Kato et 
al. (J. Biol. Chem. 1991, 266:3361) can be used. 
Where the therapeutic molecule is a nucleic acid, admin 
istration can be achieved by an appropriate nucleic acid 
expression vector which is administered so that it becomes 
intracellular, e.g., by use of a retroviral vector (see U.S. Pat. 
No. 4,980.286), or by direct injection, or by use of micropar 
ticle bombardment (e.g., a gene gun; Biolistic, Dupont), or 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
32 
coating with lipids or cell-Surface receptors or transfecting 
agents, or by administering it in linkage to a homeobox-like 
peptide which is known to enter the nucleus (see e.g., Joliot et 
al., Proc. Natl. Acad. Sci. USA 1991, 88:1864-8), etc. Alter 
natively, the nucleic acid can be introduced intracellularly and 
incorporated within host cell DNA for expression, by 
homologous recombination. 
The vector pcDNA, is an example of a method of introduc 
ing the foreign cDNA into a cell under the control of a strong 
viral promoter (CMV) to drive the expression. However, 
other vectors can be used (see EXAMPLES 13 and 15). Other 
retroviral vectors (such as pRETRO-ON, Clontech), also use 
this promoter but have the advantages of entering cells with 
out any transfection aid, integrating into the genome of target 
cells only when the target cell is dividing (as cancer cells do, 
especially during first remissions after chemotherapy) and 
they are regulated. It is also possible to turn on the expression 
of a nucleic acid by administering tetracycline when these 
plasmids are used. 
Other plasmid vectors, such as pMAM-neo (Clontech) or 
pMSG (Pharmacia) use the MMTV-LTR promoter (which 
call be regulated with steroids) or the SV10 late promoter 
(pSVL, Pharmacia) or metallothionein-responsive promoter 
(pBPV. Pharmacia) and other viral vectors, including retro 
viruses. Examples of other viral vectors include adenovirus, 
AAV (adeno-associated virus), recombinant HSV, poxviruses 
(vaccinia) and recombinant lentivirus (such as HIV). These 
vectors achieve the basic goal of delivering into the target cell 
the cDNA sequence and control elements needed for tran 
scription. The present disclosure includes all forms of nucleic 
acid delivery, including synthetic oligos, naked DNA, plas 
mid and viral, integrated into the genome or not. 
Having illustrated and described methods for treating 
hemophilia A or B by oral administration of a therapeutically 
effective amount of F.VIII or F.IX, respectively, it should be 
apparent to one skilled in the art that the disclosure can be 
modified in arrangement and detail without departing from 
Such principles. In view of the many possible embodiments to 
which the principles of our disclosure may be applied, it 
should be recognized that the illustrated embodiments are 
only particular examples of the disclosure and should not be 
taken as a limitation on the scope of the disclosure. Rather, the 
Scope of the disclosure is in accord with the following claims. 
We therefore claim as our invention all that comes within the 
Scope and spirit of these claims. 
We claim: 
1. A method for increasing hemostasis in a subject having 
hemophilia A in which clotting factor VIII (F.VIII) is defi 
cient and wherein the subject does not have F.VIII inhibitors, 
comprising orally administering to the Subject a therapeuti 
cally effective amount of F.VIII in water sufficient to induce 
oral tolerance and Supply exogenous F.VIII to the Subject, 
wherein the F.VIII is not present in a liposome. 
2. The method of claim 1, wherein the hemophilia A is a 
result of impaired expression of the F.VIII, and the F.VIII is 
administered as long as the hemophilia A persists. 
3. The method of claim 1, wherein increasing hemostasis 
comprises decreasing blood clotting time. 
4. The method of claim 1, wherein the F.VIII is adminis 
tered in absence of an anti-immune therapy. 
5. The method of claim 1, wherein the therapeutically 
effective amount of F.VIII is at least 5 mg of F.VIII per 1 kg 
of subject daily. 
6. The method of claim 1, wherein the therapeutically 
effective amount of F.VIII is at least 50 mg of F.VIII per 1 kg 
of subject daily. 
7. The method of claim 1, wherein the subject is a mammal. 
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8. The method of claim 7, wherein the mammal is a human. 
9. The method of claim 1, wherein the F.VIII is obtained 
from milk of a non-human transgenic mammal. 
10. The method of claim 9, wherein the mammal is a pig. 
11. The method of claim3, wherein the blood clotting time 
is measured using an activated partial thromboplastin time 
(APTT) assay. 
12. The method of claim 1, wherein oral administration is 
achieved by feeding the subject a therapeutically effective 
amount of the F.VIII. 
13. The method of claim 1, further comprising administer 
ing to the Subject an isolated recombinant nucleic acid mol 
ecule encoding the F.VIII, wherein the F.VIII is expressed in 
the subject. 
14. A method for orally administering a recombinant clot 
ting factor VIII (F.VIII) to a subject for treatment of hemo 
philia A in which F.VIII is deficient, wherein the subject does 
not have F.VIII inhibitors, comprising orally administering 
water containing recombinant F.VIII to the subject at a thera 
peutically effective amount Such that hemostasis in the Sub 
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ject is increased and oral tolerance of F.VIII is induced, 
thereby treating the hemophilia A. 
15. The method of claim 14, wherein the water comprises 
at least 2 g recombinant F.VIII per liter of water. 
16. The method of claim 15, wherein the F.VIII is obtained 
from milk of a non-human transgenic mammal. 
17. The method of claim 16, wherein the mammal is a pig. 
18. The method of claim 17, wherein the recombinant 
F.VIII is presentata concentration of about 2g per liter of the 
milk. 
19. A method of increasing hemostasis in a mammal hav 
ing hemophilia A, comprising orally administering to the 
mammal 5-50 mg/kg/day of clotting factor VIII (F.VIII), 
wherein F.VIII is in water but not present in a liposome, and 
wherein the F.VIII induces oral tolerance of the F.VIII and 
Supplies exogenous F.VIII to the mammal, thereby increasing 
hemostasis in the mammal. 
20. The method of claim 19, wherein the F.VIII is orally 
administered to the mammal every other day. 
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